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B-cell lymphoma-9 (BCL9) is a recently identified co-activator of β-catenin mediated 
transcription. BCL9 has been shown to promote tumor metastasis in multiple myeloma and colon 
carcinoma.  However, BCL9’s role in a switch from non-invasive to invasive cancers has not 
been recognized.  By utilizing two unique in vivo models of human non-invasive to invasive 
breast cancers, tandem ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) and 
mouse-intraductal models, we have shown for the first time that BCL9 may be an important 
molecular switch in the malignant transition of at least a subset of non-invasive cancers by 
enhancing canonical WNT signaling and promotion of epithelial-mesenchymal transition (EMT). 
Analysis of RNA and protein at distinct stages of DCIS to IDC using both models showed BCL9 
up-regulation to be associated with DCIS transition to IDC. In vivo silencing of BCL9 led to 
inhibition of DCIS invasion and reversal of EMT. Reverse phase protein analysis (RPPA)on 
DCIS cell lines Knockdown (KD) BCL9 vs. control indicated that BCL9 KD showed decreased 
expression of a number of genes in the EGFR signaling pathway, including p-EGFR, p-HER2, p-
STAT3, and p-Src. In addition, BCL9 was evaluated as a biomarker of DCIS risk of recurrence. 
Analysis of 28 DCIS patients revealed high nuclear BCL9 expression to be associated with 
pathologic characteristics known to be correlated with an increased risk for recurrence: ER and 
PR negative, high nuclear grade, and HER2 positive (p <0.05). Analysis of the TCGA database 
showed BCL9 to be highly amplified in many cancers including breast, bladder and liver.  
Furthermore, BCL9 was amplified in a significantly higher proportion of invasive basal breast 
cancers compared to other subtypes.  
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We conclude that BCL9 plays a key role in the malignant transition of a subset of non-
invasive breast cancers and may promote invasion through enhancement of canonical WNT, 
EGFR and STAT3 signaling.  The data also support that BCL9 is a potential biomarker to 
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1.1. Ductal Carcinoma in Situ (DCIS): 
Ductal carcinoma in situ (DCIS) is a non-invasive precursor lesion of breast carcinoma in 
which the malignant cells proliferate inside the duct without invading the surrounding stromal 
tissue. The American Cancer Society estimated that 60,290 new cases of breast carcinoma in situ 
will be diagnosed in 2015. Carcinoma in situ accounts for 20% of all breast cancers, and 83% of 
these lesions are DCIS.  
The natural history of DCIS is not well understood. Studies from DCIS cases that were 
initially misdiagnosed as benign suggest that 14-53% of the cases will become invasive in 10-15 
years [1], while autopsy studies reveal a higher incidence of undetected DCIS in the population 
[1], which means that not all lesions progress to invasive disease. Thus, a large percentage of 
DCIS patients are over-treated. Therefore, molecular characterization of DCIS is extremely 
important to identify biologically and clinically meaningful molecules that can serve as 
therapeutic targets and/or as biomarkers for risk stratification.  
DCIS classification:  
Multiple classification systems have been proposed to standardize diagnosis of DCIS. The 
traditional classification system is based on the predominant microscopic growth pattern, which 
includes: cribriform, comedo, solid, papillary and micropapillary [2]. Other classifications are 
based on the degree of differentiation (resemblance to normal cells), mitotic activity, and the 
presence or absence of central necrosis, most of which classify DCIS into three grades: well 
(grade 1), moderately (grade 2), and poorly (grade 3) differentiated DCIS [2]. 
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On the molecular level, Allred et al. evaluated 25 pure DCIS cases for 392 genes that define 
intrinsic subtypes of invasive breast cancer (IDC). Their gene expression profiling subclassified 
DCIS into luminal, human epidermal growth factor receptor 2 (HER2) overexpressing and basal.  
These subtypes existed at the same frequencies as previously shown for IDC (44%, 8%, and 
28%, respectively) [3]. These findings reflect the complexity of DCIS, and demonstrate that the 
heterogeneity of breast cancers arises at the early non-invasive stages in DCIS. 
Current therapies of DCIS: 
DCIS treatment is controversial, and the ultimate goal is breast conservation and reduction of 
future risk of invasion. The National Adjuvant Breast and Bowel Project (NSABP) initiated a 
prospective randomized trial (NSABP-B17) that compared the risk of ipsilateral breast tumor 
recurrence (IBTR) after lumpectomy alone to IBTR after lumpectomy followed by radiation. 
Women treated with lumpectomy plus radiotherapy had a 60% lower risk of IBTR compared 
with patients treated with lumpectomy only [4, 5]. Mastectomy showed no difference in survival 
from lumpectomy and is reserved for patients with multicentric disease, large lesions, other 
contraindications to breast conservation, or a personal preference for mastectomy [6]. The third 
treatment option is adjuvant therapy with tamoxifen or with aromatase inhibitors after surgery in 
Estrogen Receptor (ER)-positive DCIS patients. Another prospective randomized trial (NSABP-
B24) evaluated the value of tamoxifen in conjunction with lumpectomy and radiotherapy in the 
treatment of DCIS. This trial showed that adding tamoxifen reduced the risk of IBTR up to 31% 
compared to lumpectomy plus radiotherapy [2, 5]. However, tamoxifen carries potentially fatal 
toxicities, such as deep vein thrombosis, pulmonary embolism and stroke [7, 8]. As previously 
mentioned, due to lack of risk stratification methods in DCIS patients, there are no reliable 
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means to identify cases that would benefit from observation alone and cases that require more 
aggressive treatment. 
Current biomarkers of high risk DCIS: 
The decision for DCIS treatment depends on the morphological classification of the lesion. 
The Van Nuys prognostic index (VNPI) is one scoring method based on grade, size, presence or 
absence of comedo necrosis and margin width [9]. This scoring system is used to determine 
whether or not the patient will benefit from radiotherapy after surgery.  
Molecular biomarkers can provide insight into the association of DCIS and risk of invasive 
progression. There are many parallels between DCIS and invasive breast cancer in regards to 
these markers and their prognostic implications. The most common biomarkers used are ER and 
progesterone receptor (PR), the expression of which are associated with less aggressive DCIS. 
ER status also drives decision making with regard to adding tamoxifen or aromatase inhibitors to 
the treatment. In addition, HER2, cyclooxygenase-2 (COX-2), Ki-67 and p53 are well-known 
DCIS markers that show higher percentage in patients with high grade/ comedo type of DCIS 
[10]. However, they are not routinely performed for DCIS patients in the clinical setting. 
Recently a recurrence scoring system (Oncotype DX®) has been developed [11]. Oncotype 
DX® is a multigene expression test, that predicts response to chemotherapy as well as recurrence 
in early-stage breast cancer patients that are node negative and ER-positive. The Oncotype DX® 
assay is performed on RNA extracted from formalin-fixed, paraffin-embedded tumor tissue and 
is analyzed using RT-PCR. For early stage breast cancer, the expression of 21 genes is measured. 
Sixteen are cancer related genes, which are then normalized to five housekeeping genes. This 21-
gene panel is a result of three independent clinical trials that analyzed 250 candidate genes in a 
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total of 447 patients and demonstrated a statistical link between these genes and distant breast 
cancer recurrence. For DCIS patients, Oncotype DX DCIS ScoreTM is a genomically validated 
diagnostic test that provides prediction of 10-year risk of local recurrence [12]. DCIS score is 
calculated using a DCIS-specific algorithm and coefficients from only 7 of the 16 cancer-related 
genes, (Ki-67, STK15, Survivin, Cyclin B1, MYBL2, PR, GSTM1). This can guide treatment 
decisions after surgical tumor removal [13]. The DCIS score was validated  by  the Eastern 
Cooperative Oncology Group (ECOG) E5194 prospective cohort study  [13]; the study showed 
that the DCIS score can predict risk of IBTR. However, participants in ECOG E5194 were 
highly selected for patients having DCIS treated by lumpectomy and with an expected low risk 
of local recurrence [13].  Therefore, the predictive value of this assay is small. Furthermore, 
physicians claim that seven genes are not enough to predict DCIS outcome and that the existing 
biomarkers are better predictors of high-risk DCIS than DCIS ScoreTM [14].  
Currently known molecular mechanisms of DCIS progression to IDC: 
The mechanism underlying DCIS progression to invasion is complex, and depends on many 
factors including epithelial cell properties and tumor microenvironment. Many studies have 
performed gene expression profiling in an attempt to elucidate molecular changes in DCIS 
epithelia that drive invasion [15-18]. Ma et al. showed extensive similarities at the transcriptome 
level among the distinct stages of progression from DCIS to IDC, and proposed that the gene 
expression profile in DCIS may reflect the invasive potential of the disease [16].   Furthermore, 
several studies performed comparative genomic hybridization (CGH) on a panel of breast 
tumors, including DCIS and IDC, and showed that the frequency of copy number alterations was 
higher in invasive tumors than that in DCIS. These studies support the hypothesis that the 
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invasive potential is already programmed in the genome of DCIS lesions [19, 20]. Yao et al. 
combined CGH with serial analysis of gene expression (SAGE) in DCIS and IDC patient 
samples. They showed that high-fold amplifications and deletions (>0.5 or less than −0.35, 
calculated based on array CGH log 2 ratio) correspond to previously identified regions (1q21, 
8q24, 11q13, 12q13, 15q26, 17q21, 20q13 and 1p32, 11q11-12, 13q, 16q24, and 17p13, 
respectively). By correlating gene expression levels and copy number within these commonly 
amplified regions of DCIS and IDC theyidentified new oncogenes, such as H2A Histone Family, 
Member J (H2AFJ) and Epidermal Growth Factor Receptor Pathway Substrate 8 (EPS8), as 
drivers of DCIS to IDC invasive progression [19]. 
The role of microenvironment in DCIS progression to IDC has been studied. The 
microenvironment consists of fibroblasts, adipocytes, endothelial cells, immune cells and 
extracellular matrix. The role of fibroblast-induced invasion is widely accepted [21]. Orimo et al. 
demonstrated that primary breast carcinoma-associated fibroblasts (CAFs) enhanced tumor 
growth in MCF7-ras xenografts when compared to normal tissue-derived fibroblasts [22].  Hu et 
al. showed that co-transplantation of CAFs with DCIS.COM cells promoted tumor growth, while 
co-transplantation with normal fibroblasts showed no change in tumor weight [23, 24]. 
Furthermore, the tumor promoting effect of fibroblasts was reversed by co-injection with normal 
myoepithelial cells [24]. Paracrine signaling can play a major role in fibroblast-epithelial 
interaction. Allinen et al. used SAGE to describe gene expression profiles of normal breast 
tissue, DCIS, and IDC [25]. This study showed extensive gene expression changes in all cell 
types during DCIS-IDC progression, specifically increased expression level of secreted proteins 
in activated fibroblasts. One of the overexpressed secreted factors was Stromal cell-derived 
factor-1 (SDF-1) that was shown to bind to tumor epithelial cells [25]. Furthermore, fibroblasts, 
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by promoting angiogenesis, enhanced tumor growth. SDF-1 secreted from CAFs were shown to 
recruit endothelial progenitor cells that promote angiogenesis and increased tumor growth [22]. 
In addition, Dang et al. performed in vitro organotypic co-culture of mammary fibroblasts with 
basal and luminal-type breast cancer cell lines. They demonstrated that fibroblasts were recruited 
selectively to basal-type DCIS-spheroids and reorganized collagen fibers to induce invasion [21]. 
This was mediated by Rho-family small GTP-binding protein (Cdc42) in fibroblasts [21].  
However, invasive progression in luminal-type DCIS-spheroids was not induced by fibroblasts 
co-culture  [21].  
The presence or absence of an intact myoepithelial cell layer is a major diagnostic feature to 
differentiate DCIS from IDC. Myoepithelial cells have a suppressor effect on tumor cell growth, 
invasion, and angiogenesis [26]. The mechanism of myoepithelial cell disappearance during 
DCIS progression is unknown. Polyak’s group highlighted the importance of myoepithelial cells 
in DCIS progression by demonstrating that normal myoepithelial cells inhibited DCIS invasion 
[24]. Molecular profiling of myoepithelial cells purified from DCIS.COM xenografts identified 
preferential activation of Transforming growth factor-β (TGFβ), hedgehog, and p63 pathway. 
They showed that collaboration of these pathways might regulate myoepithelial phenotype. 
Inhibiting TGFβ and hedgehog pathway activity via downregulation of TGFBR2/SMAD4 and 
Gli2 expression, respectively, led to myoepithelial loss and progression to invasion [3].  
A study by Ma and colleagues on DCIS stromal cells showed upregulation of Matrix 
Metalloproteinases (MMPs) such as MMP11, MMP2, and MMP14 in the stroma associated with 
DCIS compared with normal breast epithelium suggesting that they may play a role in DCIS 
progression.  This group also showed that WNT inhibitors such as secreted Frizzled-related 
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protein (sFRPs) and WNT-inhibitory factor (WIF) were downregulated in stroma associated with 
DCIS suggesting that aberrant activation of WNT signaling in the tumor epithelia can be a 
consequence of down-regulation of its inhibitors in the surrounding microenvironment [15]. 
Another key step in DCIS to IDC transition is extracellular matrix (ECM) degradation. 
Proteolytic enzymes MMP2 and MMP9 were shown to be expressed at higher levels in DCIS 
compared to normal and hyperplastic epithelia, while MMPs 1, 2, 3, 9, and 11 were found to be 
upregulated in adjacent stromal tissue [23].  The interplay of these proteolytic enzymes on ECM 
degradation may play a role in DCIS progression.  
In vivo models of premalignant breast cancer:  
Multiple transgenic mouse models of premalignant breast lesions have been identified. 
Transgenes have been developed with a variety of promotors, combinations of different genes 
and knockouts including genes functioning as growth factors, receptors, signal transducers, and 
cell cycle proteins [27]. An example of these transgenic mice are the whey acidic protein 
(WAP)-TAg transgenic mice/BALB/c. In WAP-TAg transgenic mice, the SV40 large tumor 
antigen expression is driven by the WAP promoter, and causes pregnancy-induced DCIS lesions. 
SV40 TAg is an inducer of cell transformation and tumor formation through its ability to 
inactivate the tumor suppressor proteins pRb and p53 [28, 29]. The MMTV-rtTA, tet-op-ERα 
mouse is a conditional tetracycline-responsive transgenic mouse model with deregulated ERα 
expression in mammary epithelial cells driven by addition of exogenous doxocycline. In the 
presence of ovarian hormones these mice develop ERα-positive ductal and lobular hyperplasias 
as well as DCIS lesions by 4 months of age. However, no palpable tumors were observed in 
these mice [28].  
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Cleared fat pad transplantation is a strategy to study premalignant lesions. The mouse 
mammary fat pad is surgically removed at three weeks of age followed by transplantation of 
hyperplastic lesions and tumors into mammary gland-free fat pads of syngeneic mice. Growing 
hyperplastic lesions can replicate their original phenotypes. Medina et al. is the first who 
developed hyperplastic alveolar nodule (HAN) models in which hyperplastic cells are developed 
in mice by different strategies such as MMTVs, chemical carcinogens [30], irradiation and  
prolonged hormonal stimulation [31]. HAN lesions are maintained by serial transplantation into 
cleared mammary fat pads, and show distinct growth properties compared to invasive lesions. 
HAN models are the basis of much information about premalignant mammary lesions and 
cancer. Mouse DCIS models improved our understanding of the molecular mechanisms 
underlying progression to invasive disease. However, these models do not recapitulate the 
architecture and complexity of human DCIS. 
 Human in mouse xenografts is another DCIS model that has been developed. In previous 
models, human DCIS cells were inoculated in Matrigel and injected subcutaneously or into 
fatpads of immunodeficient mice. This is not ideal, since the cells are introduced outside their 
natural environment. Recently, Behbod and colleagues established a novel human xenograft 
model: the mouse intraductal (MIND) model. This model involves the injection of primary 
human DCIS or DCIS cell lines intraductally through the cleaved nipple of immunodeficient 
mice. This model mimics the natural progression of the disease and the DCIS microenvironment 
inside the ducts [32]. Furthermore, Valdez et al. demonstrated that primary DCIS cells grow and 
proliferate in MIND xenografts, and that DCIS biomarkers in xenografts are similar to the 
original patient samples’ biomarkers [33]. However, one limitation of this model is that DCIS 
cells are transplanted into immunodeficient mice, which may mask effects of immune cells in 
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tumorigenesis. To date, only two DCIS cell lines are utilized as xenograft models, DCIS.COM 
and SUM225, both of which are described in detail in chapter two.  
In this dissertation, DCIS.COM and SUM225-MIND models were utilized to screen for gene 
expression changes in DCIS cells during progression to IDC. Analysis of gene expression 
profiles from our in vivo model showed WNT signaling pathway was one of the top upregulated 




1.2. WNT signaling pathway: 
WNTs consist of 19 secreted glycoproteins that play key roles in various processes, including 
cell proliferation, survival, migration, cell fate, and self-renewal. WNTs regulate downstream 
pathways through both: β-catenin-dependent (canonical) and β-catenin-independent (non-
canonical) mechanisms. There are ten reported Frizzled (FZD) receptors, along with receptor 
tyrosine kinases, Receptor Tyrosine Kinase-Like Orphan Receptor 1 and 2 (ROR1 and 2), and 
RTK-like protein (RYK) that stimulate WNT signaling. 
Canonical WNT signaling is activated when FZD and LDL- receptor-related protein (LRP) on 
the target cells bind WNT proteins. These receptors transduce a signal to several intracellular 
proteins including Dishevelled (DVL), Glycogen Synthase Kinase-3β (GSK-3β), casein kinase 
Iα (CKIα), Axin, Adenomatous Polyposis Coli (APC), and the transcriptional regulator, β-
catenin.  In the absence of WNT signaling, a destruction complex containing GSK-3/APC/Axin 
controls cytoplasmic β-catenin levels. APC and Axin are scaffold proteins that facilitate kinase 
binding. CKIα and GSK-3 are serine/threonine kinases that phosphorylate β-catenin to be 
recognized by β-TrCP and directs it towards proteosomal degradation. When WNT signaling is 
active, phosphorylation of β-catenin is inhibited and hence its degradation. β-catenin will 
accumulate in the cell and translocate to the nucleus. Nuclear β-catenin will interact with other 
co-factors to stimulate transcription of WNT target genes such as lymphoid enhancer-binding 
factor 1/T cell-specific transcription factor (LEF/TCF), and B-Cell Lymphoma 9 (BCL9)/ B-Cell 






Figure 1.1. The canonical Wnt signaling pathway and its identified small molecular 
inhibitors and activators.  (Obtained from Anastas, et al 2013) Illustrates canonical Wnt 
signaling pathway in the presence (A), and absence (B) of Wnt stimulation.   
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Activators and inhibitors of WNT signaling:  
WNT signaling can be regulated at various levels by different inhibitors and activators. These 
effectors can act extracellularly or intracellularly. WNT inhibitors can naturally exist and are 
divided into six families of secreted and four families of transmembrane inhibitors.  
Secreted WNT inhibitors known to date are: Dickkopf proteins (DKKs), sFRPs, WIF-1, 
Wise/SOST, Cerberus, and Insulin-like growth-factor binding protein 4 (IGFBP-4). Among 
these, the DKK family is the best characterized. They are secreted glycoproteins that composed 
of four members 1-4. DKK3 is different from other members in that it regulates TGF-β signaling 
and has no effect on WNT signaling. DKK1 and 2 inhibit WNT signaling by high affinity 
binding to LRP5/6. DKK1 prevents WNT-LRP6 interaction and disrupts FZD8-LRP6 formation 
[35]. sFRP family of inhibitors act by sequestering WNTs away from active receptor complexes, 
thus inhibiting WNT signaling. The mechanisms of action of WIF-1, Wise/SOST, Cerberus, and 
IGFBP-4 are not fully understood. However, silencing of WIF-1 by promoter hypermethylation 
in primary human osteosarcomas is associated with loss of differentiation and increased tumor 
cell proliferation [36]. In addition, manipulation of WIF-1 and IGFBP-4 expression impedes 
biological cancer processes such as tumor cell proliferation and degree of differentiation [37]. In 
addition to secreted WNT inhibitors, transmembrane WNT inhibitors include: Shisa, Waif/5T4, 
and Adenomatosis polyposis coli down-regulated 1 (APCDD1). Shisa proteins reside in the 
endoplasmic reticulum, and inhibit WNT and fibroblast growth factor (FGF) signaling by 
suppressing FZD and fibroblast growth factor receptor (FGFR) maturation [38]. Waif1a is a 
plasma membrane protein and a WNT/β-catenin signaling target shown to activate non-canonical 
WNT signaling and to antagonize canonical WNT signaling by binding to LRP6 and regulating 
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LRP6 subcellular localization [37, 39]. APCDD1 is a membrane bound glycoprotein and a direct 
target of WNT signaling [40] that inhibits WNT/β-catenin signaling by binding to WNT3A and 
possibly preventing FZD from binding WNT [37]. 
Well known activators of WNT signaling are: R-spondins and Norrin. The R-spondin family 
(Rspo1-4) are secreted growth factors that synergize with WNTs and require WNTs to activate 
WNT/β-catenin signaling through LGR4 and LGR5 [41]. Rspo binds LGR4 and 5 causing 
subsequent phosphorylation and internalization of LRP5/6, followed by inhibition of GSKβ and 
stabilization of β-catenin [41]. Previous studies revealed a possible role of Rspo2 and 3 to 
promote tumorigenesis in vivo [42]. Norrin is a small secreted factor structurally unrelated to 
WNT but functionally equivalent. It cooperates with FZD4 and activates WNT signaling through 
LRP5/6 [43].  
Deregulation of WNT signaling in cancer:  
Aberrations in WNT signaling and alterations in tumor suppressor and oncogenic pathways 
can collaborate to drive cancer initiation and progression. Most of the observed WNT pathway 
mutations in cancer lead to hyperactivation of WNT/β-catenin signaling. 
On the receptor level, over expression of several WNT receptors was found in different 
cancers compared to normal tissues; for example, FZD6 in B-cell leukemias and lymphomas 
[44], and FZD7 in gastric carcinomas [45] and in colon cancers [46]. Inhibition of FZD7 
decreased proliferation and progression of colon cancer [47] and hepatocellular carcinomas [47]. 
In addition, ROR1 and ROR2 knock-down decreases growth of gastric, lung, breast, and renal 
carcinoma in xenograft models. Stimulation of various types cancer cells with different WNT 
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ligands have multiple effects on the growth and survival. WNT3A and WNT7A promote 
stabilization of β-catenin and activate growth of myeloma cells and prostate cancers [48]. 
WNT5A and WNT11 act as growth suppressor of ovarian cancer and hepatocellular carcinoma, 
respectively [49, 50]. 
In addition, APC deletions in colon crypt progenitors induce growth of adenomas [51]. 
Missense mutations of β-catenin that disrupt phosphorylation and degradation were observed in 
hepatocellular carcinomas, medulloblastomas and ovarian cancers [52-54]. Furthermore, high 
levels of nuclear β-catenin correlate with poor prognosis in breast and colon cancers [55, 56]. 
In this dissertation, the discovery of a new role of BCL9 in promoting breast cancer 
progression through the enhancement of WNT signaling is described.  
WNT signaling in breast cancer:  
Historic studies of MMTV-Wnt1 transgenic mice, which overexpress Wnt1 in mammary the 
mammary epithelium, showed that these mice will develop extensive ductal hyperplasia early in 
life which will further progress into mammary carcinomas [57]. Previous studies sought 
evidence of mutations that stabilize β-catenin in breast cancer, such as mutations in the N-
terminal region of β-catenin, and loss of function mutations in APC and Axin. Interestingly, no 
β-catenin mutations have been reported in breast cancer [58]. Furthermore, APC and Axin 
mutations were found to be very rare, as only a single case out of 227 breast carcinomas was 
found to have APC truncation [59, 60]. Other mutations in surface proteins such as Frizzled 
receptors and LRP5/6 have not yet been investigated [60]. On the WNT protein level, some 
reports showed that several tumors overexpress WNTs 2,3,4, and 7B [61]. 
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WNT signaling was also shown to support self-renewal in both normal and cancer stem cells. 
Tumors in transgenic mice expressing Wnt1, β-catenin and c-Myc were more enriched in 
progenitor populations that express keratin-6 (K-6) and stem cell antigen-1 (Sca-1) compared to 
transgenic mice expressing HER2  and H-ras [62]. Furthermore, a study by Zeng, et al. showed 
that WNT reporter positive cells were enriched for mammary stem cells based on Lin−, CD24+, 
CD29hi markers [63]. In the same study, Wnt3A was shown to promote self-renewal of 
mammary stem cells in vitro and to enhance their ability to reconstitute mammary glands in mice 
[63].  
A more recent study by Jang, et al. showed a correlation between negative (GSK3β) and 
positive (TCF4) regulators of WNT/β-catenin signaling and breast cancer stage. In addition, 
inhibition of WNT/β-catenin signaling pathway by knocking down WNT1 expression 
preferentially reduced metastatic potential by altering cancer stem cell activity in 4T1 mouse 
xenograft model of breast cancer [64]. 
In addition, previous studies indicated that activation of WNT signaling pathway may 
promote epithelial to mesenchymal transition (EMT), for example, WNT1, stabilized β-catenin, 
and Axin2 induced EMT in MCF7 cells [65]. An interesting study by Dr. Weinberg’s group [66], 
demonstrated that sequential exposure of the luminal EpCAM-positive subpopulation of primary 
human mammary epithelial cells to TGF-β, canonical and non-canonical WNT signaling resulted 





Therapeutic targeting of WNT pathway:  
There are several strategies to target WNT signaling, which comprise small molecules, 
blocking antibodies and peptide agonists and antagonists. Small molecular inhibitors are 
promising therapies that modulate WNT signaling at many levels. The Porcupine inhibitor-IWP 
(Inhibitor of WNT Production) inhibits palmitoylation of WNTs, preventing their secretion and 
signaling activity. Tankyrase inhibitors enhance Axin stability and degradation of β-catenin. 
Pyrvinium promotes β-catenin phosphorylation and degradation through casein kinase activation. 
However, the above inhibitors are not suitable when hyperactivation in WNT/β-catenin pathway 
is due to mutations in APC and Axin1. To overcome this challenge, inhibitors that target 
downstream signaling components are required, and some studies have identified molecules that 
inhibit interactions between TCF7L2 and β-catenin [67].  
Blocking antibodies that target WNT and WNT receptors such as anti-FZD7, FZD10 and LRP 
can inhibit cell growth and induce apoptosis of cancer cells [68, 69]. They are now in 





1.3. B-cell CLL/lymphoma 9 protein (BCL9):  
BCL9 resides on chromosome 1q21. Willis et al. discovered human BCL9 in a leukemia cell 
line and showed that the break point translocation of chromosome 1 t(1;14)(q21;q32) in this line 
falls in the 3’UTR of BCL9 gene. This translocation results in 50x increase in BCL9 expression 
[70]. BCL9 function was first described by Kramps and coworkers [71]. They reported that Lgs, 
a homolog of human BCL9 in Drosophila, functions as an adaptor protein that physically links 
Pygopus (PYGO) to the β-catenin-TCF complex, and that recruitment of PYGO is required for 
β-catenin to function as a transcriptional coactivator in Drosophila [71].  
BCL9 is composed of 1426 amino acids, and shares with B-cell CLL/lymphoma 9 Like 
(BCL9L) three conserved (in Drosophila, Zebrafish, and mammals) regions called homology 
domains (HD1, HD2, and HD3). In addition, Sustmann et al. identified two more homology 
domains that are conserved between BCL9 and BCL9L in vertebrates (not in Drosophila), and 
discovered a transactivation domain in the C terminal region about 170 amino acids in length. 
This study revealed that BCL9 is not just an adaptor protein for PYGO but can function 
independently of PYGO binding and synergizes with the C terminal domain of β-catenin in a 
cell-type-specific manner [72]. 
BCL9 binding partners: 
BCL9 binds β-catenin and activates transcription and translocation into the nucleus [71]. 
Residues 352-374 of human BCL9-HD2 form an alpha helix that pack against the groove in first 
armadillo repeat of β-catenin [73]. Thus, the BCL9/β-catenin binding site serves as a novel drug 
target for cancers with oncogenic WNT signaling and altered BCL9 expression [73]. BCL9 is an 
essential adaptor protein to recruit other cofactors including PYGO1 and PYGO2. The HD1-
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BCL9 domain binds to Homeodomain (PHD) of PYGO1 and the complex increases PYGO1 
affinity to histone H3 Lys 4 methylation. In chapter three discovery of a novel interaction 
between BCL9 and STAT3 has been described and STAT3 signaling activity was evaluated in 
BCL9 knockdown DCIS cell lines. 
BCL9 in disease:  
BCL9 variants are linked to mental disorders such as schizophrenia [74]. Microduplications 
and microdeletions of 1q21, the chromosomal location of BCL9, are associated with mental 
retardation, autism and congenital abnormalities [75]. In addition, BCL9 has a critical role in 
myogenic progenitor cell fate. Brack et al. generated conditional BCL9 deletion in the myogenic 
lineage in mice. This group observed that BCL9 deletion resulted in muscle degeneration and 
abrogation of myogenic differentiation [76]. BCL9 and other WNT pathway genes such as 
FZD5, DVL2, LRP5 and TCF7L1 were shown to be upregulated in tissue samples from 
osteoarthritic patients [77]. This observation suggests that BCL9 plays a role in pathogenesis of 
osteoarthritis. 
BCL9 as an oncogene:  
Mani et al. provided the first evidence that BCL9 can act as an oncogene [78]. BCL9 is 
overexpressed in colon cancers and multiple myelomas, and its aberrant expression increases 
proliferative, metastatic and angiogenic properties of cancer cells [78]. Deka et al. utilized 
conditional BCL9 knockout in the intestinal epithelium to examine the role of BCL9 in epithelial 
homeostasis and stem cell maintenance. The study demonstrated that ablation of BCL9 
expression decreased LGR5-positive intestinal stem cell population and impaired mucosal 
regeneration in mutant mice. Furthermore, BCL9 knockout adenocarcinomas showed reduced 
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expression of EMT and stem cell–associated genes [79]. Several studies evaluated BCL9 in 
hepatocellular carcinoma (HCC). For example, Wang et al. identified BCL9 as a molecular 
driver in HCC and reported that BCL9 location at 1q21 was amplified in 8.7% of HCCs. The 
same study showed a correlation between copy number and BCL9 expression levels, as well as a 
correlation between BCL9 protein expression by immunohistochemistry and mRNA expression 
levels in primary HCCs. SiRNA mediated knockdown of BCL9 decreased cell growth and 
survival in both proliferation and colony formation assays in HCC cell lines that showed BCL9 
gene amplification [80]. Another study by Hyeon et al. evaluated BCL9 protein expression in 
288 primary HCC patients. In normal hepatocytes, 3-10% of cells expressed weak to moderate 
cytoplasmic staining while in HCC BCL9 was observed in the nuclei. The study demonstrated 
that BCL9 might be a marker of shorter disease free survival after curative hepatectomy [81]. 
Furthermore, DNA copy number analysis in esophageal cancers revealed that more than 50% of 
the tumors showed gains in 1q21 centered on BCL9 and MUC1 [82]. This indicated that aberrant 
BCL9 expression might be found in these tumors and might play a role in tumorigenesis. 
However, there are no reports about BCL9’s role in breast cancer pathogenesis.  
Regulation of BCL9:  
To date there are limited studies on transcriptional regulation of BCL9. At the post 
transcriptional level, Jia et al. demonstrated that BCL9 is regulated by miR-30c-2* in ovarian 
cancer cell lines. A potent growth factor-like molecule called lysophophatidic acid (LPA) can 
induce the expression of miR-30c-2* thus reducing cellular proliferation in SKOV-3 and 
OVCAR-3 cells [83]. Zhao et al. demonstrated that BCL9 is regulated by the miR-30 family in 
multiple myeloma (miR-30a/b/c/d/e) [84]. In addition, Large Tumor Suppressor 2 (LATS 2), a 
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member of the canonical Hippo signaling pathway, was shown to be a negative regulator of 
WNT/β-catenin signaling through inhibiting BCL9 recruitment by β-catenin to WNT target gene 
promoters [85]. These studies suggest that BCL9 may be therapeutically inhibited by targeting 
upstream modulators of BCL9.  
Targeting BCL9:  
Targeting β-catenin/BCL9 transcriptional complex is a potential new strategy to inhibit 
oncogenic WNT signaling. Variable approaches have been explored including stabilized alpha-
helix peptides of BCL9, which were shown to inhibit tumorigenicity of colon cancer and 
multiple myeloma cell lines in vitro and in vivo [86, 87]. Small molecule compounds such as 
carnosic acid have been identified to disrupt β-catenin/BCL9 binding [88]. Furthermore, 
inhibition of BCL9 translation with miRNAs can be used as another approach, since miR-30-5p 
inhibits BCL9 expression in multiple myelomas [84, 89]. 
Efforts to block binding of PYGO-BCL9 complex to methylated histone H3 tail have been 
documented to prevent activation of β-catenin oncogenic signaling. Miller et al. utilized nuclear 
magnetic resonance (NMR) to screen for small molecular inhibitors of PHD-HD1 interaction in 
the PYGO-BCL9 complex. They identified two benzothiazole compounds that bound to the 










Expression Profiling of In Vivo Ductal Carcinoma In Situ 
Progression Models Identified B Cell Lymphoma-9 as a 




Ductal carcinoma in situ (DCIS) is a complex pathologic condition in which malignant breast 
epithelial cells proliferate inside mammary ducts but do not invade the surrounding stroma. 
Modern screening technologies have made DCIS a more common diagnosis than in the past, but 
insufficient understanding of DCIS biology has limited advances in therapy. For example, can a 
subset of DCIS patients be safely monitored with a “watchful waiting” as has been adopted for 
certain prostate cancers in men?  As it now stands, a large proportion of DCIS cases are over-
treated, since it is estimated that, if left untreated, only 25-50% of cases progress to invasive 
cancer [8, 91, 92]. Given the current understanding of DCIS, it remains challenging to reliably 
stratify DCIS lesions with appropriate sensitivity and specificity to predict progression to 
invasion [8]. My first aim for this dissertation is to identify key molecular mechanisms 
underlying DCIS progression to IDC, which is addressed in this and next chapters. 
It is generally agreed that the molecular profiles of DCIS and IDC are similar and that the 
genetic program necessary for invasive progression already exists in the pre-invasive stages of 
breast cancer [16, 93]. However, there are conflicting reports making this area of research worth 
further exploration. For example, one study suggested there might be gene dosage changes 
during the transition from DCIS to IDC [19]. Liao and colleagues found differential genomic 
copy number aberrations in DCIS with an invasive potential compared to pure DCIS by array 
comparative genomic hybridization (aCGH) [20]. Another study found amplification of distinct 
loci restricted to a specific population of cancer cells in 3 of 13 matched DCIS to IDC pairs [94].  
Collectively, these latter studies suggest that unique genomic aberrations in some cancer cells or 
distinct population of cancer cells may drive DCIS to IDC. 
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Herein, sequential and temporal changes in gene expression during DCIS invasive 
progression are characterized by utilizing two systems: DCIS cell line-derived mouse intraductal 
(MIND) xenograft models (SUM225 and DCIS.COM) and a tandem DCIS/IDC model which 
uses samples from patients afflicted with DCIS that are synchronous with IDC within the same 
breast. Both models involve DCIS non-invasive to invasive transition and provide valuable tools 
for studying the temporal molecular changes associated with DCIS invasive transition. 
The MIND is a novel DCIS in vivo model that has been developed by Dr. Behbod’s group 
[32]. MIND involves injection of DCIS cell lines or cells derived from primary patient DCIS 
within mammary ducts of immunocompromised mice. MIND xenotransplantation is a realistic 
human DCIS model because it mimics the entire process of DCIS progression, including ductal 
growth as in situ lesions followed by their invasion as they escape the natural barriers of normal 
myoepithelial cells and the basement membrane. As previously reported by our group [32], 
DCIS.COM MIND xenografts generate basal-like lesions and become invasive by 10 weeks 
post-injection, whereas those generated by SUM225 cells generate HER2 over-expressing 
luminal lesions that invade the myoepithelial layer by 14 weeks. The second model includes 
tandem DCIS/IDC lesions. The lesions are identified radiologically by an area of clustered 
microcalcifications adjacent to (contiguous with) an invasive mass and sampled by core biopsy. 
For these studies, six pairs were collected and analyzed by RNA sequencing for differential gene 
expression comparing DCIS to the corresponding IDC. 
Molecular profiling of both in vivo DCIS progression models revealed a significant increase 
in BCL9 mRNA and protein expression when comparing non-invasive to invasive lesions in our 
DCIS cell line MIND xenografts and in five of six DCIS/IDC tandem lesions. BCL9 is a recently 
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identified WNT pathway activator, which plays an important role in transcriptional activity of β-
catenin in association with LEF/TCF family members [95]. BCL9 plays a critical role in 
progression of colorectal cancers and multiple myeloma by activating WNT oncogenic signaling 
[78]. However, the role of BCL9 in mammary gland biology and breast cancer has not been 
explored previously. In this chapter, we propose that there is evidence that BCL9 serves as a 
molecular driver of EMT and DCIS invasion by enhancing canonical WNT signaling. Therefore, 
BCL9 may serve as a potential therapeutic target for prevention of IDC. 
2.2. Materials and Methods 
Animals and animal surgeries: Mouse surgeries were performed on 8- to 10-week-old 
virgin female NOD-SCID IL2Rgammanull (NSG) mice that were either bred or purchased from 
Jackson Laboratories (Bar Harbor, ME, USA) as previously described [32]. Animal experiments 
were conducted following protocols approved by the University of Kansas School of Medicine 
Animal Care. 
Cell culture: DCIS.COM and SUM225 were purchased from Asterand, Inc. (Detroit, MI) in 
2007 and were maintained according to the supplier's guidelines. Both cell lines have been 
authenticated by genomic profiling validating the ER-/PR-/HER2+ status of the SUM225 cells 
and the ER-/PR-/HER2- expression pattern in the DCIS.COM [96]. 
Tandem lesions biopsies: All human experiments were approved by the University of 
Kansas Medical Center Institutional Review Board (IRB).  All patients gave written informed 
consent for participation in this research. Recruits included patients undergoing image-guided 
core needle biopsy due to suspicion of DCIS or IDC. In all cases, research specimens were 
obtained only after acquisition of diagnostic specimens. Our radiologists applied minimally 
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invasive ultrasound guided selective tissue harvest of contiguous lesions with a “tandem” 
appearance and provided us with biopsy cores from each region. Biopsy tissue was placed in 
preservation media (LiforCell, Lifeblood Medical, Inc., Freehold, NJ) and stored at 4°C on ice 
until RNA isolation. 
RNA Isolation, Quantitative PCR (qPCR): Total RNA was isolated with miRNeasy Mini 
Kit (Qiagen #217004) using the manufacturer's protocol, and cDNA was synthesized from 250 
ng of total RNA with miScript Reverse Transcription Kit (Qiagen #218061). TaqMan® Gene 
Expression Master Mix (Applied Biosystems #4369016) and TaqMan® Gene Expression 
assays were used. Primers specific for human BCL9 (Applied Biosystems #Hs00979216_m1) 
were utilized and target gene expression was normalized to human β-actin (Applied Biosystems 
#Hs99999903_m1). The standard curve method was used for quantification. Reactions were 
performed in the StepOnePlus™ Real-Time PCR System [97]. 
Statistical analysis: Data are presented as mean normalized expression ± s.e.m.  Unless 
otherwise noted, one-way analysis of variance (ANOVA) was used for statistical comparisons. A 
value of P≤0.05 was considered significant.  
Microarray gene expression profiling and analysis: We utilized DCIS MIND models, a 
novel model developed in our laboratory which most closely mimics the human DCIS 
environment, with both SUM225 and DCIS.COM cell lines to characterize sequential and 
temporal changes in mRNA expression over a time course of 2, 6, and 10 weeks during in vivo 
progression in the epithelial cells. Microarray technology was utilized to analyze gene expression 
profiles from RNA isolated from magnetically sorted epithelial cells from MIND xenografts at 2, 
6 and 10 weeks post-injection.  For these studies, five mice per replicate (3 replicates) per time 
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point (3 time points; 2, 6, and 10 weeks) for each cell line (two cell lines; DCIS.COM and 
SUM225) were used. The mammary epithelial cells were magnetically sorted from five mice at 
each time point per replicate. After sorting, Qiazol extraction of total RNA was performed 
according to the manufacturer's instructions. Labeling was performed using the GeneChip 3' IVT 
Express Kit (Affymetrix) which utilizes an oligo dT based reverse transcription reaction 
followed by a T7 promoted in-vitro transcription biotin labeling reaction. Hybridization was 
performed using the GeneChip Hybridization, Wash and Stain Kit (900720). Platform used was 
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. GeneChips were scanned 
using the Affymetrix GeneChip Scanner 3000 7G.  Raw mRNA expression values from the 2, 6 
and 10 week samples were normalized and converted to the log2 scale. Data was median-
centered and analyzed by unsupervised average-linkage hierarchical clustering using Cluster 3.0 
software (http://bonsai.hgc.jp/~mdehoon/software/cluster/cluster3.pdf). The computed data 
matrix was then uploaded into Java TreeView software and visualized as heatmaps 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm#ctv). Clustering of expression 
data from DCIS.COM and SUM225 cell lines revealed that the majority of expression changes 
had already occurred at the 6-week time point with few changes occurring from 6 to 10 weeks. 
This suggests that mechanisms of invasion are already in place by 6 weeks. Further analysis 
focused on the 2 to 6 week time-frame. 
Significance analysis for microarrays (SAM) software was utilized to determine differentially 
expressed genes between the 2 to 6 week time-point in both DCIS.COM and SUM225 cell lines 
(http://statweb.stanford.edu/~tibs/SAM). The cut-off for significance was determined by <5% 
false-discovery rate. Two-class unpaired SAM analysis generated a list of significant genes and 
fold-change values between 2 and 6 weeks in DCIS.COM (18,590 down regulated; 10,227 up-
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regulated) and SUM225 (19,953 down regulated and 14,691 up-regulated). These genes were 
further analyzed using QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood 
City,www.qiagen.com/ingenuity). IPA software integrates expression changes with known 
molecular interactions and disease processes (http://www.ingenuity.com). The WNT/β-catenin 
canonical pathway was identified as a significantly upregulated pathway in both cell line-MIND 
xenografts during transition from 2 to 6 weeks. The raw and analyzed microarray data have been 
deposited in NCBI's Gene Expression Omnibus [21] and are accessible through GEO Series 
accession number: GSE65890 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65890) 
[21, 22]. 
RNA Sequencing & Analysis: Total RNA was prepared using (All prep Qiagen Kit) 
according to the manufacturer’s protocol. Libraries were prepared by illumina TruSeq RNA 
Sample Preparation Kit (A cat#FC-122-1001, B cat#FC122-1002) according to the 
manufacturer’s protocol. The DCIS and IDC samples were sequenced using a HiSeq2500 
2x100bp version 3 sequencing run.  Eight sample libraries were multiplexed 4 per lane resulting 
in 46.9X – 58.2X coverage per sample. Four sample libraries were multiplexed 2 per lane 
resulting in 107.4X – 124X coverage per sample. Paired Fastq sequence files were imported to 
CLC Genomics Workbench (version 7.5) and mapped to the human reference genome (hg19) 
using approach previously described [98]. Ensembl database (GRCh37.74.gtf) was used for gene 
annotation. Total number of reads mapped to the gene was used as the total counts for the gene, 
and the values were transformed by adding 1 followed by log2 transformation.  Transformed 
data was quantile normalized before analyzing differential gene expression between two groups 
(DCIS vs IDC). Empirical analysis of differential gene expression was performed between two 
groups (DCIS vs IDC) using ‘Exact Test’ as previously described [99].     
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Raw and analyzed RNA sequencing data were deposited in NCBI's Gene Expression 
Omnibus [21] and are accessible through GEO Series accession number: GSE66301 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66301) [21, 22]. 
Immunofluorescence staining (IF): IF was performed as previously described [33]. 
Antibodies are listed in Table 2.1. Nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI; Vector Laboratories, # H-1200). Negative controls were carried out using 
secondary antibodies without primary antibodies. Imaging was performed on a laser-scanning 
confocal microscope (Model 510; Carl Zeiss MicroImaging, Inc, Thornwood, NY, USA). The 
acquisition software used was Pascal (Carl Zeiss MicroImaging, Inc). Fluorescence quantitation 
and analysis was done using imageJ (http://imagej.nih.gov/ij/). Images were analyzed for area of 
selection, mean gray value, and integrated density. Both the areas of interest and their 
background were measured, then the corrected total cell fluorescence (CTCF) was calculated by 
the following formula: CTCF = Integrated Density – Area of selected cells X Mean fluorescence 
of background readings. 
Plasmids, Transfection, and Luciferase Reporter Assay: Plasmid constructs: pSuper8X–
TOPFlash reporter (Addgene plasmid 12456) and Super 8x FOPFlash (TOPFlash mutant) 
(Addgene plasmid 12457) were provided by Randall Moon via Addgene [100]. Renilla luciferase 
plasmid phRG was from Promega. The β-catenin△N (Addgene plasmid 19288) construct was 
acquired from Eric Fearon via Addgene [101]. PCDH-BCL9 (BCL9-OE), PLKO.1-BCL9-
shRNA (BCL9-KD) (CCTCTGTTGAATATCCCTGGAA) and PLKO.1-non-silencing control 
(Control) were acquired from Dr. Carrasco [78]. pGIPZ Human BCL9 shRNA (BCL9 KD 2) 
(TGCAAACTTGGACATTCGA), and pGIPZ-non-silencing control (Control 2) obtained from 
Dharmacon (#RHS4430-200265260). Transfection: DCIS.COM and SUM225 were transfected 
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with electroporation using Amaxa TM Cell line Nucleofector kit V (Lonza #VCA-1003), while 
HEK293T cells were transfected using Lipofectamine 2000 reagent (Invitrogen #11668-027) 
according to manufacturer’s protocols. Luciferase assay was performed using Dual-Luciferase® 
Reporter Assay System (Promega #E1910). 
Lentivirus production: Glycerol stocks of pLKO.1 shRNA-based BCL9 and PLKO.1 non-
silencing control were cultured with 100 µg/ml of ampicillin (Amresco # 0339) and plasmids 
were purified using HiSpeed Plasmid midi kit (Qiagen #12643). Preparation of viral particles 
was performed by co-transfecting individual pLKO.1 vectors (10 µg), packaging plasmid 
pCMV-dR8.2 (contains Gag, Pol, Rev, and Tat) (Addgene plasmid 8455; 5 µg), and the envelope 
plasmid pCMV-VSVG (Addgene plasmid 8454; 5 µg) in HEK293T cells. Both plasmids were 
acquired from Robert Weinberg via Addgene [102]. Transfection was performed in a 10 cm 
plate, nearly 75% confluent using Lipofectamine 2000 transfection reagent (Invitrogen #11668-
027) in antibiotic free Opti-MEM media (Invitrogen #51985-034) following manufacturer’s 
protocol. Media was collected after 48, 72, and 96 h of transduction, pooled and subjected to 
ultracentrifugation at 80,000 x g for 2 hours (Beckman Coulter, Optima L-100 XP, 70Ti rotor) at 
room temperature. Pellets of the concentrated viral particles were re-suspended in 250 µl of 
DMEM (GIBCO #21063029), and stored in aliquots at -80oC until further use. Lentiviral titers 
were measured using Lenti-XTM p24 Rapid Titer kit (Clontech #632200). Transduction was 
performed at an MOI of 3 and 20 for DCIS.COM and SUM225, respectively, and cells continued 
to grow in the presence of puromycin (Thermo Scientific #100552). For various experiments, 
transduced cells from up to 5 passages were used. 
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MTS, invasion and migration assays: For MTS assays, Cell Titer 96® Aqueous Non-
Radioactive Cell Proliferation Assay (Promega #G5421) was used according to the 
manufacturer’s protocol. Transwell assays were used to measure invasion and migration. The 
upper and underside of the transwells (Corning #3422) were coated with Corning™ Matrigel™ 
Membrane Matrix (Fisher Scientific #CB-40230) (1mg/ml in serum free media) for the invasion 
assay, and with Corning TM Human Fibronectin (Fisher scientific #CB-40008) (50 µg/ml 
PBS/0.1% gelatin) for migration assay. DCIS.COM and SUM225 cells were starved of serum for 
24 h prior to use. Cells were irradiated at 10 gray and 2.5 × 104 cells were plated in serum free 
media in the upper well. Percent area of migration and invasion were analyzed in DCIS.COM 
and SUM225 cells after 24 and 96 hours, respectively. Invasion and migration were determined 
by ImageJ (http://imagej.nih.gov/ij/) analysis of microscopic images. 
For in vivo invasion studies, BCL9-KD, non-transduced (NT), and scrambled shRNA control 
(control) SUM225 and DCIS.COM cells were injected at 10,000 cells per gland. A total of 3 
glands and 3 animals in control groups, 5 glands and 4 animals in KD groups and 4 glands in 4 
animals in NT groups were examined. Glands were collected at 10 and 14 weeks post-intraductal 
injection in DCIS.COM and SUM225 xenografts, respectively. Mammary glands containing 
DCIS-like lesions were then fixed, embedded and sectioned at 5 µm. Every 10th section was 
stained with H&E to identify sections with the greatest xenograft growth for each gland. Then 4 
sections adjacent (2 sections on each side) to the one with the greatest growth were prepared for 
IF as described above, stained for human-specific K5/K19, SMA and counterstained with DAPI. 
Imaging was performed as described above. Invasive lesions were identified by the lack of a 
SMA-expressing myoepithelial layer. LSM image browser was used to measure the maximum 
distance of an invasive lesion to the closest DCIS lesion in each section. To determine the 
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number of invasive lesions per section, confocal images (20x magnification) were taken of all 
invasive lesions and counted. Measurements (i.e.distance of invasion and number of invasive 
lesions) for the 4 sections were averaged to represent each gland. Data were presented as the 
maximum distance of invasion (µm) and number of invasive areas in each section. 
Western blot analysis and co-immunoprecipitation: For co-immunoprecipitation, 1000 μg 
of protein was incubated with antibodies at 4oC overnight followed by centrifugation at 3000 
rpm for 1 min in 4oC. Supernatants were incubated with Protein A/G PLUS-Agrose beads (Santa 
Cruz #sc-2003) at 4°C for 1 hour, followed by a wash in PBS. Proteins bound to the beads were 
eluted with SDS-loading buffer at 99°C for 5 min and then loaded for western blot, and 2µg of 
whole cell lysates were loaded as input. Western blots analysis was carried out as previously 
described [103]. For western blots, 25 µg of DCIS.COM and 50 µg of SUM225 cell lysates were 
loaded into each lane. Antibodies used are listed in Table 2.1. 
FACS analysis and magnetic sorting: Cells were stained at a final concentration of 1∶20 for 
30 min on ice followed by washes in Hanks' Balanced Salt Solution (Invitrogen #24020-117) 
containing 2% fetal bovine serum. Antibodies used are listed in Table 2.1. FACS and data 
analysis were performed using the BD LSR II flow cytometer and FlowJo software (Tree Star).  
Magnetic sorting was performed using Easy Sep® human Epcam positive selection kit (Stem 





 Company Catalog # Isoty
pe 
IF staining       
Primary antibodies    
BCL9 Abcam 37305 Rabbit 
BCL9L Abcam 113110 Rabbit 
Cytokeratin 5 Vector VPC400 Mouse 
Cytokeratin 19 Thermoscientific MS198 Mouse 
SMA Thermoscientific PA5-18292 Goat 
Phospho-histone3 Abcam ab47297 Rabbit 
Cleaved caspase 3 Cell signaling 9664S Rabbit 
Secondary antibodies    
Alexa Fluor 488 anti-rabbit Invitrogen A11008 Goat 
Alexa Fluor 594 anti-mouse Invitrogen A21203 Donkey 
Alexa Fluor 488 anti-mouse Invitrogen A11012 Goat 
    
Co-immunoprecipitation       
IgG Cell signaling 2729S Rabbit 
BCL9 Santa Cruz sc-68915 Rabbit 
    
Western blot analysis       
BCL9 Abcam 37305 Rabbit 
β-catenin BD 610153 Mouse 
β-actin Chemicon MAB1501 Mouse 
BCL9L Abcam 113110 Rabbit 
    
FACS analysis       
Human CD44 (PE)-conjugated BD Pharmingen 555479  
Human CD24 (FITC)-conjugated 
 
BD Pharmingen 555427  
Table 2.1. List of antibodies and sources for use in immunofluorescence staining, co-





BCL9 up-regulation is associated with DCIS epithelia that progress to invasion. To 
explore the temporal molecular changes associated with DCIS non-invasive to invasive 
transition, DCIS cell line MIND models as well as DCIS/IDC tandem lesions were utilized. 
Mammary glands containing DCIS-like lesions were excised followed by digestion to isolate 
epithelial cell components at three time points: 2, 6 and 10 weeks post injection. These time 
points were selected in order to accurately reflect the molecular changes, as the DCIS lesions are 
formed between 2-6 weeks and progress past the myoepithelial layer and the basement 
membrane by 10 weeks, Figure 2.1. To separate human DCIS epithelial cells from mouse 
mammary cells, EpCAM-positive cells were magnetically sorted followed by RNA isolation and 
microarray analysis. The majority (>90%) of DCIS.COM and SUM225 cells express EpCAM, 
Figure 2.2. Additionally, we performed RNA sequencing of patient DCIS/IDC tandem lesion 





Figure 2.1. A figure depicting the MIND model.  MIND xenografts were generated by 
intraductal injection of DCIS.COM and SUM225 cells into the mammary ducts of 
immunocompromised mice. Mammary glands containing DCIS-like lesions were collected at 
the distinct stages of in situ to invasion (2, 6 and 10 weeks) followed by digestion, magnetic 




Figure 2.2. The majority of SUM225 and DCIS.COM cells are EPCAM-positive by flow 
analysis. Representative flow analysis of (A) SUM225 (left) and DCIS.COM cells (right) for 
EpCAM (black line) compared to isotype control (grey line) show that 95% of SUM225 cells 
and 99% of DCIS.COM cells are EPCAM positive. (B) Histogram overlaying SUM225 and 




Figure 2.3. Differentially expressed genes in DCIS.COM and SUM225 MIND 
xenografts. (A) (B) Heatmap of differentially expressed genes in DCIS.COM and SUM225 
MIND xenografts at 2, 6 and 10 weeks. Unsupervised average-linkage hierarchical clustering 
of expression data from DCIS.COM and SUM225 MIND xenografts revealed that the 
majority of expression changes occurred at the 2 to 6-week time point with few changes 
occurring from 6 to 10 weeks.  
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The analysis was focused on canonical WNT signaling since a recent report by Scheel and 
colleagues demonstrated that the collaboration of three signaling pathways, TGF-β, canonical 
and non-canonical WNT signaling induced and maintained an EMT state in mammary epithelial 
cells [66]. Acquisition of an EMT-like phenotype is believed to be the initiating event prior to 
cell invasion. An EMT-like phenotype can result from aberrant basal differentiation program in 
differentiated luminal/epithelial cells or in stem/progenitor cells [104]. Furthermore, this study 
showed that pre-treatment of epithelial cells with WNT activators followed by TGF-β and down 
regulation of E-cadherin resulted in a synergistic enhancement in EMT and cellular migration. 
These data suggest that WNT signaling is the earliest event in the process of EMT and cellular 
invasiveness. A candidate gene in the canonical WNT signaling pathway, B cell lymphoma-9 
(BCL9), was selected since it was found to serve as a co-factor of β-catenin in early 2000 
[71][71]; however, there were no previous studies on the role of BCL9 in breast cancer. BCL9 is 
located on chromosome 1q21, a common amplified region in breast cancer [105]. Analysis of 
microarray data from MIND samples showed canonical WNT signaling to be among the 
significantly upregulated pathways in our dataset (Figure 2.4, Table 2.3 and 2.4), BCL9 was 
significantly upregulated in the transition from DCIS to IDC (q value <5%)  (Figure 2.4). BCL9 
expression was assessed in six pairs of DCIS/IDC tandem lesions by RNA sequencing. Tandem 
DCIS/IDC are defined as DCIS lesions that have concurrent IDC within the same breast (Figure. 
2.5). The analysis of tandem lesions' RNA sequencing data for BCL9 expression comparing 
DCIS to IDC is shown in (Figure. 2.6).  This analysis showed a significant upregulation in 




  Figure 2.4. Differentially expressed Wnt genes in DCIS.COM and SUM225 MIND 
xenografts. (A) (B) Heatmap of differentially expressed genes in the canonical Wnt pathway 
from 2 to 6 weeks in DCIS.COM (A) and SUM225 (B) MIND xenografts. Unsupervised 
average-linkage hierarchical clustering was used to visualize significantly up or down-
regulated genes in the WNT pathway, using a cut off of <5% false-discovery rate.   
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Table 2.2 Significant differentially expressed WNT genes in DCIS.COM 
Gene Symbol Probeset ID Fold Change q-value(%) 
APC 203525_s_at 2.181328 0 
APC 216933_x_at 1.486683 0 
BCL9 204129_at 1.868612 0 
CSNK1E 225756_at 2.220647 0 
CTNNB1 223679_at 5.370228 0 
DVL2 57532_at 1.9175 0 
DVL3 201908_at 2.35002 0 
FBXW2 235195_at 2.415927 0 
FZD1 204451_at 4.327389 0 
FZD1 204452_s_at 2.212632 0 
FZD3 227499_at 1.919654 0 
LRP6 225745_at 2.14176 0 
SOSTDC1 213456_at 5.450216 0 
TCF7L2 216035_x_at 1.533357 0 
TCF7L2 212761_at 1.706515 0 
TCF7L2 216037_x_at 1.583251 0 
WNT3 229103_at 1.804226 0 
WNT5A 231227_at 1.307759 0 
WNT6 71933_at 0.672037 0 
CSNK1E 226858_at 1.871161 1.493429 
FBXW2 241736_at 1.219233 1.493429 
FZD2 210220_at 1.374081 1.493429 
FZD3 227524_at 1.470612 1.493429 
FZD6 203987_at 1.953449 1.493429 
LOC100289775 / 
WNT7B 
217681_at 1.385542 1.493429 
LRP6 34697_at 1.381827 1.493429 
PAFAH1B1 200816_s_at 1.695291 1.493429 
WNT16 224022_x_at 1.257333 1.493429 
AXIN2 222695_s_at 0.812279 1.929012 
LRP4 212850_s_at 0.793273 1.929012 
PAFAH1B1 200815_s_at 0.662306 1.929012 
WNT5B 223537_s_at 0.78629 2.805836 
DVL1 203230_at 1.628244 2.893519 
FZD7 203705_s_at 1.729794 3.858025 
PAFAH1B1 211547_s_at 1.482621 3.858025 
WNT10B 206213_at 1.087355 3.858025 
AXIN2 222696_at 1.194988 4.822531 
CSNK1E 222015_at 1.154453 4.822531 
DKK1 204602_at 2.476747 4.822531 
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DKK2 219908_at 1.283061 4.822531 
DKK3 221127_s_at 1.25915 4.822531 
FRAT1 219889_at 1.310318 4.822531 
FZD3 219683_at 1.325252 4.822531 
FZD7 203706_s_at 1.448601 4.822531 
PAFAH1B1 200813_s_at 1.280911 4.822531 
TCF7L2 216511_s_at 1.442822 4.822531 
TCF7L2 212759_s_at 1.225253 4.822531 
WNT4 1556689_a_at 1.205825 4.822531 
 
Table 2.3 Significant differentially expressed WNT genes in SUM225 
Gene Symbol Probeset ID Fold Change q-value(%) 
APC 203525_s_at 6.057196 0 
APC 216933_x_at 2.169045 0 
BCL9 204129_at 1.323798 0 
CSNK1E 226858_at 3.687441 0 
CSNK1E 225756_at 1.577529 0 
CSNK1E 222015_at 1.230732 0 
CTNNB1 223679_at 2.762147 0 
DKK1 204602_at 11.25073 0 
DKK3 230508_at 0.664939 0 
DKK4 206619_at 0.526069 0 
DVL1 203230_at 2.73491 0 
DVL2 57532_at 2.135484 0 
DVL3 201908_at 7.646926 0 
FBXW2 235195_at 3.579538 0 
FBXW2 241736_at 0.76398 0 
FRAT1 219889_at 1.426774 0 
FZD1 204451_at 5.947582 0 
FZD1 204452_s_at 1.556699 0 
FZD3 227499_at 1.661159 0 
FZD3 219683_at 1.659379 0 
FZD6 203987_at 12.95946 0 
FZD7 203705_s_at 2.378315 0 
FZD7 203706_s_at 4.391103 0 
LRP5 229591_at 0.551967 0 
LRP6 225745_at 4.805578 0 
NKD2 232201_at 0.672158 0 
PAFAH1B1 200816_s_at 2.173113 0 
PAFAH1B1 200815_s_at 0.541757 0 
ROR2 205578_at 1.371724 0 
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RSPO1 241450_at 0.697006 0 
RSPO4 237423_at 0.562388 0 
SOSTDC1 213456_at 5.66075 0 
TCF7L2 212761_at 5.207148 0 
WNT2B 206459_s_at 0.619857 0 
WNT5A 213425_at 2.623568 0 
WNT5B 223537_s_at 0.626067 0 
WNT6 71933_at 0.534937 0 
WNT6 221609_s_at 1.902601 0 
WNT7A 210248_at 0.67367 0 
AXIN2 224498_x_at 0.701802 1.399177 
AXIN2 224176_s_at 0.604779 1.399177 
AXIN2 222695_s_at 0.634325 1.399177 
AXIN2 222696_at 1.99963 1.399177 
CSNK1E /// 
LOC400927 
234943_at 0.716845 1.399177 
FBXW2 218941_at 0.63113 1.399177 
FZD5 206136_at 0.704201 1.399177 
FZD9 207639_at 0.613408 1.399177 
LRP4 212850_s_at 0.606795 1.399177 
LRP5 209468_at 0.664687 1.399177 
LRP6 205606_at 0.710998 1.399177 
PYGO2 239666_at 0.724729 1.399177 
TCF7L2 212762_s_at 3.431922 1.399177 
WNT10A 223709_s_at 0.668815 1.399177 
WNT10B 206213_at 0.681931 1.399177 
WNT16 221113_s_at 0.669338 1.399177 
WNT2 205648_at 0.720831 1.399177 
WNT4 230751_at 0.686089 1.399177 
WNT5B 221029_s_at 0.736215 1.399177 
FBXW2 1560752_at 0.743755 1.499118 
PAFAH1B1 211547_s_at 1.467588 1.499118 
RSPO3 228186_s_at 0.693411 1.499118 
WNT4 1556689_a_at 0.796031 1.499118 
WNT6 222086_s_at 0.751168 1.499118 
WNT5A 205990_s_at 2.160168 1.967593 
TCF7L2 216037_x_at 1.401197 2.698413 
DKK3 214247_s_at 0.810754 2.73752 
WNT11 206737_at 0.746879 2.73752 
WNT3 221455_s_at 0.735102 2.73752 
WNT3 231743_at 0.79694 2.73752 
WNT7B 238105_x_at 0.727763 2.73752 
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DKK3 221126_at 0.785168 3.881279 
LOC100289775 /// 
WNT7B 
217681_at 0.837705 3.881279 
NKD1 1553115_at 0.795197 3.881279 
PAFAH1B1 200813_s_at 1.331175 3.881279 
TCF7L2 216511_s_at 1.405792 3.881279 
RSPO2 1554012_at 0.905963 4.088504 
TCF7L2 236094_at 0.844567 4.088504 
  
Table 2.2. and 2.3 WNT pathway specific genes differentially expressed in DCIS.COM 
and SUM225 MIND xenografts during transition from 2 to 6 weeks. Significant 
differentially expressed genes between the 2 to 6 week time-point in both DCIS.COM and 
SUM225 cell lines were further analyzed using QIAGEN’s Ingenuity Pathway Analysis® 
(IPA). The WNT/β-catenin canonical pathway was identified as a significantly upregulated 




Figure 2.5. Radiographic (A) and H&E stain (B & C) images of a patient’s DCIS/IDC 
tandem lesion.  A: 3-D ultrasound image of a tandem lesion. (B) H&E of a biopsy taken 
from the DCIS and (C) the IDC regions.  Insets: Lower magnification of B. & C. respectively, 




Figure 2.6. BCL9 expression in DCIS/IDC tandem samples. Normalized log2-transformed 
expression of BCL9 was plotted and tandem lesions between paired DCIS and IDC are 
connected by a line to indicate their relationship.  The results indicate a significant increase in 




     To confirm the microarray analysis, RT-qPCR was performed on EpCAM-positive cells 
sorted from an independent set of DCIS cell line MIND xenografts as they progressed from 2 to 
10 weeks. BCL9 gene expression showed a significant increase at 10 compared to 2 weeks in 
both SUM225 and DCIS.COM MIND xenografts (62 ± 14 and 35 ± 12 -fold increase, 
respectively; mean ± s.e.m, P<0.05) (Figure 2.7). Furthermore, immunofluorescence (IF) 
staining of the MIND xenografts demonstrated increased nuclear BCL9 expression as DCIS 
lesions progressed to invasion (Figure. 2.8). There have been a few reports on the role of 
BCL9L (BCL9-2 or B9L), BCL9 homolog, in breast cancer.  One study showed nuclear BCL9L 
expression to be significantly associated with high nuclear grade and expression of HER2 in 
breast cancers [106]. Another study reported that BCL9L induced ER positive breast cancers in 
vivo by regulating expression of ER through a ß-catenin independent mechanism and predicted 
therapeutic response to tamoxifen [107]. Human BCL9 and its homolog BCL9L reside on 
chromosome 1q21 and 11q23.3, respectively. Both BCL9 and BCL9L function as co-activators 
of β-catenin-LEF/TCF mediated transcription [108]. Expression patterns of BCL9 and BCL9L 
were compared in DCIS cell line MIND xenografts as well as on tissue sections obtained from 
23 DCIS with IDC patients and 14 pure DCIS patients. As shown in Figure. 2.9, BCL9L 
expression was mainly cytoplasmic, while BCL9 expression was primarily nuclear. Furthermore, 
RT-qPCR showed no significant increase in BCL9L expression in DCIS MIND xenografts 
during invasive transition from 2 to 10 weeks (Figure 2.10). A Western blot on cell lysates 
obtained from DCIS cell lines also showed no change in BCL9L expression with BCL9 KD 
(Figure 2.10).  Therefore, results in both MIND and tandem lesions support the hypothesis that 
increased BCL9 expression is associated with DCIS transition to invasion, while the data do not 




Figure 2.7. RT-qPCR of BCL9 in EpCAM-positive epithelial cells sorted from SUM225 (A) 
and DCIS.COM (B) MIND xenografts at 2, 6, and 10 weeks post-intraductal injection. Bar 





























Figure 2.8. Enhanced BCL9 nuclear expression in DCIS cell line MIND xenografts that 
progress to invasive lesions. IF staining of BCL9, K5/K19, and DAPI in SUM225 (A) and 
DCIS.COM (B) MIND xenografts at 2, 6, and 10 weeks post-intraductal injection, merged 
channels are shown in the upper panels and BCL9 only channels are shown in the lower 
panel. BCL9 is conjugated to Alexa-Fluor 594, shown in red, and keratin 5/keratin 19 are 
conjugated to Alexa-Fluor 488, shown in green. Nuclei are counterstained with DAPI. Scale 







Figure 2.9. BCL9 showed increased nuclear expression, while BCL9L expression 
remained cytoplasmic during DCIS invasive transition. (A) Immunofluorescence staining 
of BCL9 (red; top panel), BCL9L (red; bottom panel), K5/K19 (green), and Hoechst (blue) in 
a primary sample that represents: Adjacent normal glands (Left), DCIS lesions (middle), and 
IDC (right). BCL9 and BCL9L are conjugated to Alexa-Fluor 594 (red) and K5/K19 are 
conjugated to Alexa-Fluor 488 (green). Nuclei are counterstained with Hoechst. Scale bars 50 








Figure 2.10. BCL9L mRNA and protein levels compared to BCL9. (A & B) RT-qPCR of 
BCL9 and BCL9L mRNA in EpCAM-positive epithelial cells sorted from SUM225 (A) and 
DCIS.COM (B) MIND xenografts at 2, 6, and 10 weeks post-intraductal injection. Bar graphs 
represent fold change normalized to 2 weeks. Data are mean values ± s.e.m (n=3, *P<0.05). 
(C) Representative western blot analysis of cell lysates from control and BCL9-KD-SUM225 
and DCIS.COM blotted with anti-BCL9, and anti-BCL9L antibodies. β-actin was used as a 
loading control. The analysis shows no change in BCL9L protein levels in BCL9-KD cells 





BCL9 knockdown (KD) inhibits the proliferative, migratory, and invasive activity of 
DCIS cells in vitro and in vivo. The canonical WNT pathway is required for normal 
development and tissue homeostasis [108]. However, aberrant activation of canonical WNT 
signaling has been implicated in the development and progression of many cancers including 
breast cancer [86]. BCL9 overexpression has been proposed as one mechanism that may 
contribute to aberrant WNT activation [78]. BCL9 possesses a potent transcription activation 
domain and might function as an oncogene by providing an alternative pathway for β-catenin 
activation and subsequent tumor progression [71]. 
To assess the role of BCL9 in promoting DCIS invasive progression, two shRNA-based 
BCL9 constructs have been utilized: shRNA1 [78] and shRNA2, as well as their corresponding 
scrambled controls (Control 1 and Control 2). Since the results for both shRNAs were similar, 
only values for the shRNA1 groups are listed here. Western blot confirmed that shRNA1 
efficiently silences BCL9 expression in both DCIS.COM (Figure 2.11A; left panel) and 
SUM225 (Figure. 2.11A; right panel). MTS assay was performed to assess the role of BCL9 on 
cell growth in vitro (Figure 2.11B). As shown in Figure 2.11B, knockdown of BCL9 
significantly suppressed growth by 0.55 ± 0.01 fold (P<0.05; compared to 1.02 ± 0.02 in control) 
in DCIS.COM and by 0.62 ± 0.01 fold in SUM225 (P<0.05; compared to 0.76 ± 0.004 in 
control). To assess the role of BCL9 on cell migration and invasion, fibronectin and reconstituted 
basement membrane (Matrigel) assays were performed, respectively (Figure 2.12). BCL9 KD 
reduced invasion of DCIS.COM cells (0.23 ± 0.03 fold, P<0.05) compared to control (0.81 ± 
0.07), and in SUM225 cells (0.62 ± 0.04 fold, P<0.05) compared to control (1.06 ± 0.05). In 
addition, cell migration in DCIS.COM BCL9 KD cells was significantly lower (0.2 ± 0.03 fold, 




Figure 2.11. BCL9-KD decreases proliferative activity of DCIS cell lines in vitro. (A) 
Western blot analysis using anti-BCL9 antibody and anti-β-actin as a loading control (top), 
and  (B) MTS assays of NT, scrambled control (control) and BCL9-KD in DCIS.COM (left 
panels) and SUM225 (right panels). Bar graphs represent mean absorbance at 490 nm 






Figure 2.12. BCL9-KD decreases migratory and invasive activity of DCIS cell lines in 
vitro. (A and B) Show representative images of the migration and invasion assays in NT, 
scrambled control (control) and BCL9-KD in DCIS.COM (A) and SUM225 (B). Bar graphs 
represent % area of cells migrated (top) and invaded (bottom) under the membrane after 24 h 
for DCIS.com and 96 h for SUM225. Invasion and migration were determined by imageJ 





reduction in SUM225 BCL9 KD cells (0.70 ± 0.23 fold, P>0.05) migration compared to control 
(1.00 ± 0.14 fold). Furthermore, re-expression of BCL9 in DCIS.COM BCL9 KD cells using a 
BCL9-overexpression lentiviral vector resulted in a significant increase in proliferation, 
migration and invasion in vitro (Figure 2.13) (P<0.05).  
To examine the role of BCL9 in invasive progression in vivo, BCL9 KD DCIS.COM and 
SUM225 cells, and control cells, were transplanted as MIND xenografts (Figure 2.14). Glands 
were collected at 10 weeks post-transplantation for DCIS.COM, and at 14 weeks for SUM225, 
and prepared for IF using antibodies for BCL9 to confirm in vivo KD, human cytokeratin 5 and 
19 (K5 and K19) to detect in vivo growth of human DCIS like lesions, smooth muscle actin 
(SMA) to detect the myoepithelial layer, phospho-histone 3 (phosphoH3) to detect cell 
proliferation, and cleaved caspase 3 to detect apoptosis. As shown (Figure 2.14A), successful in 
vivo KD was achieved in both DCIS.COM and SUM225. Extent of invasion was analyzed by 
measuring maximum distance traveled by invasive cells past the myoepithelial layer of each 
mammary duct, and by counting the number of invasive lesions per gland (Figure 2.14B). As 
shown in Figure 2.14C, BCL9 KD DCIS.COM and SUM225 MIND lesions showed a 
significant reduction in maximum distance of invasion (DCIS.COM= 78.0 ± 22.3 μm in KD 
compared to 302.7 ± 12.4 μm in control and for SUM225=75.5 ± 18.9 μm in KD compared to 
338.3 ± 18.8 μm in control; P<0.05) and in the number of invasive lesions per field compared to 
control (DCIS.COM=1.4 ± 0.5 in KD compared to 4.3 ± 0.9 in control and for SUM225= 3.0 ± 
3.0 invasive lesions in KD compared to 11.7 ± 1.2 invasive lesions in control; P<0.05). As 
shown in Figure 2.15, BCL9 KD DCIS.COM and SUM225 showed a significant reduction in 







Figure 2.13. MTS, migration and invasion assays in DCIS.COM cells that were 
previously transduced with scrambled control (Control) or BCL9 KD shRNA. The 
control cells and BCL9 KD cells were re-transduced with empty vector (EV), BCL9 
overexpression (BCL9-OE) and BCL9 KD. BCL9-OE was achieved by transduction using the 
PCDH-BCL9 (BCL9-OE) acquired from Dr. Carrasco. (A) MTS assay on control cells 
transduced with EV (control+EV), or BCL9-OE (control+BCL9-OE), BCL9-KD transduced 
with EV (BCL9 KD+EV), and BCL9-KD transduced with BCL9-OE (BCL9 KD+BCL9-OE). 
Bar graphs represent mean absorbance at 490 nm normalized to control ± s.e.m (n=6). (B and 
C) Show representative images of the migration and invasion assays. Bar graph represent % 
area of cells migrated (left) and invaded (right) under the membrane after 24 h. Invasion and 
migration were determined by image J analysis of microscopic images per sample, the data 







Figure 2.14. BCL9-KD inhibits invasion in DCIS cell line MIND xenografts. (A) IF 
staining of BCL9 (red), K5/K19 (green), and DAPI (blue) in DCIS.COM (left) and SUM225 
(right), control and BCL9-KD MIND xenografts at 10 and 14 weeks post-intraductal 
injection, respectively. (B) IF staining of K5 (red), SMA (green), and DAPI in DCIS.COM 
cells demonstrating how distance of invasion was measured. Scale bars=50 μm, 40x 
magnification. (C) Bar graphs represent the maximum distance of invasion and number of 
invasive lesions in control and BCL9-KD for DCIS.COM and SUM225 MIND xenografts. 








Figure 2.15. BCL9-KD decreases epithelial cell proliferation in vivo. (A) Bar graphs 
represent the number of phosphoH3-positive cells per 500 cells. Data represent the mean ± 
s.e.m (n=4, *P<0.05). (B) IF staining of control and BCL9-KD DCIS.COM and SUM225 
MIND xenografts stained with the proliferation marker phosphoH3 -green, and K5/K19 -red, 









Figure 2.16. BCL9-KD causes no significant change in epithelial cell death in vivo. (A) 
Bar graphs represent the number of cleaved caspase 3-positive cells per 500 cells. Data 
represent the mean ± s.e.m (n=4, *P<0.05). (B) IF staining of control and BCL9-KD 
DCIS.COM and SUM225 MIND xenografts stained with cleaved caspase 3 green, and 







500 KD cells compared to 5.25 ± 0.25 cells per 500 control cells counted; SUM225=7.83 ± 0.01 
cells per 500 KD cells compared to 21.5 ± 2.36 per 500 control cells counted; P<0.05).  
However, there was no change in the number of cleaved caspase 3 positive cells (Figure 2.16). 
These data demonstrate that BCL9 promotes in vivo cellular proliferation and invasion, while 
BCL9 is not involved in cell survival and viability. 
BCL9 regulates expression of EMT biomarkers. Previous studies in colon carcinoma and 
multiple myeloma models showed that tumors with BCL9 KD exhibited altered expression and 
distribution of mesenchymal and epithelial markers, vimentin, β-catenin and E-cadherin, 
indicative of reduced EMT [78]. Likewise, Deka, J and Colleagues [79] showed that mice with 
conditionally deleted Bcl9/Bcl9l in intestinal cells exposed to a carcinogen (dimethylhydrazine 
followed by DSS) showed higher expression of both WNT target genes that regulate EMT 
(vimentin, fibronectin and β-catenin) and stem cell related genes such as Sox6 compared to wild 
type. Based on these data, we assessed the role of BCL9 on expression of EMT biomarkers in 
our DCIS cell lines. A western blot was performed on cell lysates derived from DCIS.COM and 
SUM225 cells that were NT, expressed a scrambled shRNA control, or BCL9-KD using 
antibodies for vimentin as a mesenchymal marker and E-cadherin as an epithelial marker. BCL9 
KD in DCIS.COM cells exhibited reduced vimentin and increase epithelial marker E-cadherin 
(Figure 2.17). SUM225 also showed an increase in E-cadherin, but control cells did not express 
vimentin, so as expected, BCL9 KD did not change vimentin expression. Overexpression of 
BCL9 (BCL9 OE) on the other hand, reduced E-cadherin and increased vimentin expression in 
DCIS.COM cells (Figure 2.17) To confirm our findings in vivo, IF staining of BCL9 KD 
DCIS.COM and SUM225 MIND xenografts, and their controls were performed using anti-




Figure 2.17. BCL9-KD reduces the mesenchymal markers and increases the luminal 
markers in DCIS cell lines. (A) Representative western blot analysis of cell lysates from NT, 
control and BCL9-KD DCIS.COM and SUM225 cells blotted with anti-BCL9, anti-vimentin, 
and anti-E-cadherin antibodies. B-actin was used as a loading control. The labels show 
percent change in BCL9-KD protein compared to control. (B) Western blot analysis with E-
cadherin and vimentin on DCIS.COM control cells transduced with EV (control+EV), or 
BCL9-OE (control+BCL9-OE), BCL9-KD transduced with EV (BCL9 KD+EV), and BCL9-











Figure 2.18. BCL9-KD reduced mesenchymal markers and increases luminal markers 
in DCIS cell lines. (A and B) show IF images of control (a-d) and BCL9-KD DCIS.COM (e-
h) xenografts stained with vimentin (A) and E-cadherin (B) shown in red, and K5 shown in 
green, and DAPI in blue. Scale bars=50 μm, 40x magnification. (C) Bar graphs of cell 
fluorescence intensity units for E-cadherin and vimentin in control and BCL9 KD 
DCIS.COM cells. Measurements were obtained by imageJ. Corrected cell fluorescence was 
calculated by subtracting the background mean density from the total integrated density. Data 








fluorescence intensity. As shown in Figure 2.18, in our DCIS.COM MIND xenografts exhibited 
a significant increase in E-cadherin expression in BCL9 KD compared to the control  (681207 ± 
198349 U compared to 120994 ± 25258 U; P<0.05) and a significant reduction in vimentin 
expression in BCL9 KD compared to control (44967 ± 5402 U compared to 400345 ± 111633 U; 
P<0.05).  DCIS.COM cells generated Basal like DCIS like lesions in vivo. However, in our 
SUM225 xenografts, there was not a significant reduction in vimentin and or upregulation in E- 
cadherin expression.  SUM225 cells generate luminal like DCIS lesions in vivo. These data 
suggest that BCL9 may have a more significant effect on EMT-like phenotype in basal cells 
compared to luminal cells. The effects of BCL9-KD on the luminal marker CD24 and the basal 
marker CD44 in DCIS.COM and SUM225 were also assessed by flow cytometry analysis of NT, 
control and BCL9-KD cells. As seen in Figure 2.19, BCL9-KD cells showed an increase in 
expression of luminal marker CD24 compared to control in DCIS.COM (77.27% ± 0.20% vs. 
90.77% ± 3.26%; P<0.05), while there was no change in SUM225 cells (data not shown). CD44 
expression levels did not change in either cell line, DCIS.COM or SUM225 (Figure 2.19B; 
SUM225 data not shown). These data confirm our previous findings that BCL9 may contribute 
to maintenance of an EMT program in some but not all cancer cell types. 
BCL9 interacts with β-catenin and enhances WNT/β-catenin signaling. BCL9 and its 
homolog BCL9L and pygopus (PYGO) were identified as co-activators for WNT/β-catenin 
transcription in Drosophila and in mammalian cells [71] [78]. To examine BCL9 and β-catenin 
interactions in our DCIS cell line models, BCL9 was immunoprecipitated from whole cell 
extracts of DCIS.COM and SUM225 cells using anti-BCL9 antibody, followed by western blot 




Figure 2.19. BCL9-KD increased CD24 positive population in DCIS.COM. (A) 
Representative flow analysis of control and BCL9-KD DCIS.COM cells for CD24 and CD44 
(top), representative histogram showing changes in CD24 (left) and CD44 (right) in control 
(blue line), BCL9-KD DCIS.com cells (yellow line) compared to isotype control (red line). 
(C) Bar graphs show the percentage of CD24 positive population in BCL9 KD and control. 








Figure 2.20. BCL9 interacts with β-catenin in DCIS cell lines. Whole cell extracts of 
DCIS.COM and SUM225 cells were immunoprecipitated for BCL9 using an anti-BCL9 
antibody, followed by western blot analysis using anti-β-catenin and anti-BCL9 antibody. IgG 







of our DCIS cell lines, DCIS.COM (Figure 2.20, left panel) and SUM225 (Figure 2.20, right 
panel). To explore whether BCL9 modulates WNT/β-catenin-mediated transcription, the 
SuperTopFlash (STopflash), a luciferase reporter assay that measures β-catenin/LEF-TCF-
mediated transcription, along with the FopFlash reporter with mutated LEF/TCF binding sites as 
a control were used. Non-transduced, control, and BCL9-KD DCIS.COM and SUM225 cells 
were transiently transfected along with STopFlash and FopFlash reporters, and treated with 
control or WNT3A conditioned medium (CM) 4 hours following transfection. Twenty-four hours 
following transfection, luciferase activity was measured. As shown in Figure 2.21A, KD of 
BCL9 significantly reduced β-catenin/TCF-mediated transcription (P<0.05) in DCIS.COM, both 
in the presence and absence of WNT3A stimulation, compared to similarly treated NT and 
controls, but not in SUM225 cells with or without WNT3a stimulation (Figure 2.21B). In order 
to assess whether BCL9 enhances β-catenin mediated transcription, BCL9 and constitutively 
active β-catenin were overexpressed in human embryonic kidney (HEK) 293T cells, which 
express low endogenous levels of BCL9 (data not shown). As expected, constitutively active β-
catenin expression increased transcription, both in the absence and presence of WNT3a 
stimulation, compared to non-transduced controls (NT; P<0.05; Figure 2.21C). Overexpression 
of BCL9 enhanced β-catenin/TCF-mediated transcription induced by WNT3A by about 2-fold 
compared to NT control (P<0.05). Furthermore, cells that overexpressed both BCL9 and 
constitutively active β-catenin showed significantly higher β-catenin/TCF-mediated transcription 
compared to β-catenin overexpression alone and in response to WNT3A stimulation (~1.7-fold 
increase; P<0.05). In addition, canonical WNT activation was analyzed in BCL9 KD 
DCIS.COM cells after re-expression of BCL9 (BCL9-KD/OE). As shown in Figure 2.21D, 








  Figure 2.21. BCL9 KD inhibits WNT/β-catenin signaling activity in DCIS.COM. 
STopFlash reporter activity in DCIS.COM (A)  and SUM225 (B) NT, control, and BCL9-
KD, that were either treated with WNT3A or control CM. (A and B-inset) FopFlash in these 
cells with control or WNT3A CM. (C) STopFlash reporter activity in 293T cells NT, BCL9-
OE, constitutively active β-catenin, or all combined that were either treated with WNT3A or 
control CM. (C-inset) FopFlash in these cells with control or WNT3A CM. Data represents 
mean ± s.e.m (n=3, *P<0.05, letters indicate statistical difference). (D) TopFlash and 
FopFlash reporter activity in DCIS.COM control cells transduced with EV (control+EV), or 
BCL9-OE (control+BCL9-OE), BCL9-KD transduced with EV (BCL9 KD+EV), and BCL9-
KD transduced with BCL9-OE (BCL9 KD+BCL9-OE). They were either treated with 









without WNT3a (1.7 ± 0.28 vs. 0.6 ± 0.13) in untreated and after treatment with WNT3a (11.42 
± 0.46 vs. 3.3 ± 0.76; P<0.05). These data demonstrate that BCL9, by binding to β-catenin, 
enhances canonical WNT activation in DCIS.COM cells (a basal cell line). While BCL9 still 
binds β-catenin in SUM225 (luminal HER2 overexpressing) it does not activate WNT canonical 
signaling that can be assessed by luciferase reporter assay. 
 
2.4.Discussion 
Canonical WNT signaling can be constitutively activated  in cancer by a variety of  
mechanisms including mutations in APC, Axin, and β-catenin [109]. These mutations enable β-
catenin to escape destruction and drive oncogenic WNT signaling [109]. However, in breast 
cancer, where mutations in APC or β-catenin are not commonly reported, BCL9 overexpression 
may be a molecular mechanism contributing to aberrant WNT activation and progression [78]. 
The mechanism by which BCL9 is overexpressed in some cancers is not entirely understood, but 
cancer genome analysis via GISTIC reveals copy number alterations in 13% of all breast cancer 
cases examined [110]. BCL9 resides on chromosome 1q (1q21). Chromosome 1q amplification 
is a common finding in several cancers including breast [111]. BCL9 is a nuclear co-factor that, 
by binding β-catenin and PYGO, modulates canonical WNT signaling and promotes β-catenin-
mediated transcription. Formation of a quaternary complex consisting of LEF/TCF, β-catenin, 
BCL9 and PYGO enhances β-catenin-dependent WNT transcriptional activity [71]. Indeed, 
BCL9 is recognized as an adaptor that helps PYGO recognize modified histone H3 tails by their 
plant homeodomain (PHD) fingers [112]. Human BCL9 and its paralog BCL9L reside on 
chromosome 1q21 and 11q23.3 respectively. Thus, the molecular regulation of these two genes 
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may be very different. One study reported BCL9L to regulate ER transcription by interaction 
with Sp1 through the proximal ESR1 gene promoter and to be highly expressed in patients with 
ER-positive breast cancers [107].  The exact role of BCL9 vs. BCL9L in normal mammary gland 
development has not been studied. In addition, we did not find BCL9L upregulation to be 
associated with invasive progression in our DCIS MIND models. Therefore, role of BCL9L in 
breast cancer remains unknown.   
Here BCL9 was identified by analysis of molecular profiling of DCIS at distinct stages of in 
situ to invasive transition. Initial findings suggested that BCL9 expression and activity in DCIS 
cells are important risk factors for breast cancer progression. This is based on the enhanced 
nuclear expression of BCL9 in DCIS epithelia that progressed to invasion. Silencing of BCL9 in 
the invasive DCIS cell line led to in vivo and in vitro inhibition of both cell growth and invasion, 
as well as down-regulation of vimentin, a biomarker of epithelial-mesenchymal transition 
(EMT). The role of BCL9 in progression of other types of cancers has been reported previously. 
However, to our knowledge, there are currently no data on the contribution of BCL9 in breast 
cancer progression. Mani and colleagues [78] showed that KD of BCL9 by shRNA in a colon 
cancer cell line (colo320) and a multiple myeloma cell line (MM1S) reduced proliferation and 
colony formation. On the contrary, overexpression of BCL9 increased colo320 and MM1S 
migration in transwell migration assays and in vitro Matrigel coated invasion assays. 
Immunocompromised mice injected with colo320 KD of BCL9 showed significant increase in 
survival and reduced lung metastasis. Likewise, mice injected with MM1S cells KD BCL9 also 
showed improved survival and reduced metastasis to long bone, spine, and head. BCL9 KD 
tumors also showed reduced EMT markers such as vimentin, E-cadherin and β-catenin.  
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It also been demonstrated in this chapter that BCL9 KD suppressed WNT signaling as 
assessed by TOP-FLASH WNT reporter assays in the basal DCIS cell line (DCIS.COM), while 
BCL9 KD in SUM225 (luminal HER2 overexpressing) did not affect the canonical WNT 
signaling. This result may indicate that the canonical WNT pathway is involved in the 
progression of certain subtypes of breast cancers, i.e. basal subtypes. This observation is 
interesting since the TCGA breast cancer data shows that BCL9 is significantly amplified in 
basal subtypes of breast cancers [110, 113]. However, there is also the possibility that TopFlash 
used in our study did not detect WNT activity since this reporter does not detect all 
transcriptional effects in WNT signaling.    
 
2.5. Conclusion: 
Collectively, the findings in this chapter suggest that BCL9, by enhancing canonical WNT 
signaling and initiating EMT, serves as an important molecular driver in invasive transition of 
human DCIS. Therefore, BCL9 may serve as a potential therapeutic target for prevention of IDC. 
However, the results obtained from the luminal DCIS cell line (SUM225) show that BCL9 is 
promoting invasion without affecting canonical WNT signaling. In chapter three we investigate 









Novel Role of BCL9 in the Activation of Other 





In the previous chapter, BCL9 was shown to promote DCIS progression to invasion in 
two representative DCIS cell lines, DCIS.COM and SUM225, in vitro and in vivo. In 
DCIS.COM cells, BCL9 promoted tumorigenesis by mediating canonical WNT signaling. 
However, in SUM225 cells, we observed lack of response to WNT3a ligand, and BCL9-KD had 
no effect on WNT reporter activity. Therefore, the mechanism by which BCL9 promotes 
invasion in SUM225 is not fully understood. Previous studies showed that the C-terminal region 
of BCL9 has two homology domains (HD4 and HD5) that are highly conserved between human, 
mouse and zebrafish, and these HD4-5 regions contain a transactivation domain that can activate 
transcription independently [72]. Interestingly, there are no known binding partners identified for 
these domains [72]. We explored the possibility that BCL9 might interact with other 
transcription factors and could be mediating crosstalk between WNT and other signaling 
pathways. Here, we performed reverse phase protein analysis (RPPA) to screen BCL9-KD and 
control DCIS cells for changes in protein expression. This screening revealed a novel role of 
BCL9 in activating Signal transducer and activator of transcription 3 (STAT3) signaling. 
STAT3 is constitutively active in 50% of breast cancers [114]. STAT3 signaling is shown 
to activate targets directly involved in proliferation, cell cycle progression and survival such as 
Cyclin D1 and C-Met, while its inhibition can impair tumor growth [115]. Furthermore, STAT3 
signaling has other biological functions in cancer such as, preparing pre-metastatic niches for 
disseminating tumor cells to colonize and metastasize [116] and promoting development of 
obesity-associated cancer through activation of inflammatory immune responses [117]. In 
addition, STAT3 signaling expands the cancer stem cell (CSC) population in breast cancer cells 
and maintains the expression of genes important for eliciting stem cell phenotype [118, 119]. 
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Traditionally, STAT3 signaling is activated mainly by cytokines such as interleukin-6 
(IL6), IL11, and Leukemia inhibitory factor (LIF), and by growth factor receptors such as 
Epidermal Growth Factor Receptor (EGFR), and HER2 receptor. Newly discovered activators of 
STAT3 pathway, such as Toll-like receptors (TLRs) and G-protein-coupled receptors (GPCRs), 
have also been reported [118]. The signaling cascade differs within these upstream activators. 
For instance, unlike receptor tyrosine kinases, IL6 receptor and TLRs lack kinase activity, they 
instead rely on Janus kinases (JAKs) to phosphorylate and activate STAT3. Upon binding of 
these ligands to their receptors, a conformational change occurs, which activates JAK. STAT3 is 
then recruited to the receptor and phosphorylated at Tyr705 which leads to its dimerization and 
translocation into the nucleus. In addition, serine/threonine kinases mediate Ser727 
phosphorylation, of which enhances STAT3 transcriptional activity (Figure 3.1). 
As described above, STAT3 has a complex role in tumorigenesis. Discovering new 
mechanisms by which this pathway exerts its cancer promoting effects will help us design and 
develop novel and effective therapeutic strategies. 
 
3.2. Materials and methods 
Cell Culture: LentiX 293T, DCIS.COM and SUM225 were purchased from Asterand, Inc. 
(Detroit, MI) in 2007 and were maintained according to the supplier's guidelines.  
Immunofluorescence staining (IF): IF was performed as previously described [33]. In 
addition to mouse anti phospho (Ser727) STAT3 (Millipore # 07-703) other antibodies are listed 
in Table 2.1. Imaging was performed on a laser-scanning confocal microscope (Model 510; Carl 
Zeiss MicroImaging, Inc., Thornwood, NY, USA). The acquisition software used was Pascal 
(Carl Zeiss MicroImaging, Inc.).  
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  Figure 3.1. Pathways  activating STAT3 signaling in cancer. The figure was obtained from 
Yu, et al 2014.  STAT3 signaling is activated by diverse receptors, which cause activation of 
JAKs and phosphorylation of STAT3 at Tyr705. Serine/Threonine kinases mediate STAT3 
phosphorylation at Ser727. STAT3 dimerizes and translocates to the nucleus; STAT3 binds 






Plasmids, transfection, and luciferase reporter assay: Plasmids for BCL9 KD were 
described in chapter two. For STAT3 signaling activity, Cignal STAT3 Reporter (luc) kit 
(Qiagen # CCS-9028L) was used. Plasmid constructs: Constitutively active STAT3 
overexpression, EF.STAT3C.Ubc.GFP (Addgene plasmid 24983) was provided by Linzhao 
Cheng via Addgene [120]. HEK293T cells were transfected using Lipofectamine 2000 reagent 
(Invitrogen #11668-027) according to manufacturer’s protocols. Luciferase assays were 
performed using Dual-Luciferase® Reporter Assay System (Promega #E1910). 
Western blot analysis and co-immunoprecipitation: For co-immunoprecipitation, 1,000 μg 
of protein was incubated with antibodies at 4oC overnight followed by centrifugation at 3000 
rpm for 1 min in 4oC. Supernatants were incubated with Protein A/G PLUS-Agrose beads (Santa 
Cruz #sc-2003) at 4°C for 1 hour, followed by a wash in PBS. Proteins bound to beads were 
eluted with SDS-loading buffer at 99°C for 5 min and then loaded for western blot. Two 
micrograms whole cell lysates were loaded as input. Western blots analysis was carried out as 
previously described [103]. For western blots, 25 µg of DCIS.COM and 50 µg of SUM225 cell 
lysates were loaded into each lane. Rabbit polyclonal anti-STAT3 (Clone:K15, Santa Cruz # 
sc483) antibody was used. The antibodies used to detect BCL9, β-catenin are listed in Table 2.1. 
Reverse Phase Protein Array (RPPA)  
RPPA lysis buffer, protease inhibitors, phosphatase inhibitors, and SDS Sample Buffer were 
provided by Cancer Proteomic and Metabolomic Core Facility at the Cancer Prevention and 
Research Institute of Texas (CPRIT). To prepare cell lysates, cells were harvested by 
trypsinization, and washed twice with cold PBS and centrifuged at 400xg for 5 minutes. The 
pellet (5x106 cells) was resuspended in 300 µl RPPA working solution (composed of 1 ml 
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protease Inhibitors, 1 ml phosphatase inhibitors, and 3 ml RPPA lysis buffer). Proteins were 
incubated on ice and vortexed every 10 minutes for 30 minutes. Lysates were centrifuged at 
14,000xg for 15 minutes at 4oC, and the supernatant was transferred to a fresh tube. BCA was 
used to determine protein concentration. 
To prepare lysates for RPPA analysis, each lysate was combined with 70 µl of 2xSDS Sample 
Buffer 3.5 µl β-mercaptoethanol, and RPPA Working Solution was added to a total volume of 
140 µl. Samples were heated for 8 minutes at 100oC, brought to room temperature, and 
centrifuged for 2 minutes at 14,000 xg. Supernatant was collected and aliquoted into three tubes 




3.3. Results            
BCL9 knockdown cells showed a significant reduction in EGFR and STAT3 signaling: 
To address whether or not BCL9 regulates other oncogenic pathways, RPPA of 200 validated 
antibodies was performed on cell lysates from DCIS.COM and SUM225 BCL9-KD or control 
cells. The array covers multiple total proteins and phosphoproteins in the following protein 
pathways or functional protein groups: epithelial-mesenchymal transition, stem cells, apoptosis, 
DNA damage, proliferation and cell cycle, growth factor receptors, cytokines/STATs, and 
nuclear receptors/transcriptional regulatory proteins. BCL9 KD decreased expression of proteins 
involved in pro-tumorigenic pathways in both DCIS cell lines. Interestingly, total and 
phosphorylated EGFR and STAT3 protein levels were also down-regulated in our dataset (Table 




DCIS.COM KD vs NS SUM225 KD vs NS 
c-Jun -1.54 c-Jun (60A8) -1.53 
Cox-2 -1.35 ILK1 -1.29 
FGFR1 2.20 Integrina4 -1.12 
HER2/c-ErbB2 1.23 KLF4 -1.18 
Integrina4 -1.21 p-AKT -1.52 
Integrinb3 -2.22 p-ALK (384)/Y1586) -1.41 
MEK6 1.22 p-AMPKb1 (S108) -1.41 
p70S6K -1.09 p-Chk1 (S345) -1.51 
p-Akt (T308) -1.70 p-Chk2 (S33/35) -1.21 





p-c-Jun (S63) -1.33 p-HER2/ErbB2 (Y877) -1.34 
p-EGFR -1.28 p-Jak1 (Y1022/1023) -1.31 
p-EGFR -1.13 p-MEK1/2 (S217/221) -1.37 
p-MEK1/2 1.90 p-p70S6K (T389) -1.25 
p-p44/42MAPK 
(Erk1/2)(T202/Y204) 1.95 p-Ret (Y905) -1.17 
p-p70S6K (T389) -1.24 p-SHC (2431)(Y317) -1.21 
p-Rb (S807/811) -1.97 p-Src (Y527) -1.44 
p-SAPK/JNK (T183/Y185) 1.50 p-STAT3 (S727) -1.15 
p-Src (Y527) -1.60 p70S6K -1.18 
p-STAT3 (S727) -1.30 Sox2 -1.22 
STAT3 -1.27 Sox9 -1.33 
  




  Table 3.1: BCL9 regulates expression of several tumorigenic factors.  Reverse Phase 
Protein Array (RPPA) was performed on DCIS.COM and SUM225 cells KD of BCL9 or 
control.  The table shows significant fold change (bold) values comparing KD to non-
silencing control.  Factors common to both cell lines are in green.  BCL9 KD decreased 
expression of several protumorigenic factors.  In DCIS.COM, BCL9 KD enhanced expression 




To determine whether or not STAT3 correlates with BCL9 in breast cancers, TCGA analysis 
of breast cancers that had alterations in BCL9 gene was performed. Data included 962 breast 
cancers, 26% of which showed BCL9 mRNA upregulation (described in chapter four). As shown 
in Figure 3.2, TCGA data showed a significant correlation between BCL9 expression and 
phosphor(Tyr705)STAT3 (P= 0.03). These data suggest that BCL9 may regulate and activate 
STAT3 either through a direct interaction, or indirectly by controlling STAT3 upstream 
regulators. 
STAT3 upregulation is associated with DCIS that progressed to invasive breast cancer: 
Before addressing the role of BCL9 in STAT3 signaling, STAT3 was evaluated in the 
DCIS.COM and SUM225 MIND models described in chapter two. As shown in Figure 3.3. 
microarray analysis revealed that STAT3 was upregulated from 2 to 6 week time point post 
intraductal injection in both cell lines (Figure 3.3). Ingenuity Pathway Analysis (IPA) of 
microarray data from DCIS.COM and SUM225 MIND xenografts, showed that genes in the 
STAT3 signaling pathway were upregulated (Figure 3.4). To confirm the microarray results, IF 
staining of DCIS.COM and SUM225 MIND xenografts with anti-phosphor(Ser727)STAT3 
antibody was performed, These studies showed BCL9 and phosphor(Ser727)STAT3 co-





Figure 3.2: TCGA data showed a significant correlation between BCL9 expression and 





Figure 3.3. STAT3 is upregulated in DCIS.COM and SUM225 MIND xenografts during 
progression. Microarray data obtained from DCIS.COM (A), and SUM225 (B)-MIND 









Figure 3.4. IPA analysis of DCIS.COM and SUM225 MIND xenografts microarray 
data. IPA analysis of the microarray data obtained from DCIS.COM (A), and SUM225 (B)-
MIND xenografts from 2 to 6 weeks post intraductal injection show upregulation of STAT3 








Figure 3.5. Phosphorylated STAT3 co-localizes with BCL9 in DCIS MIND xenografts 
during progression. Immunofluorescence staining of SUM225 at 10 weeks post-intraductal 
injection. BCL9 is conjugated to Alexa-Fluor 594, shown in red, and p(Ser727)STAT3 is 
conjugated to Alexa-Fluor 488, shown in green. Merged BCL9 and pSTAT3 shows co-
localization points in yellow (white arrows). Nuclei are counterstained with DAPI. Scale bars 





BCL9 binds STAT3 and enhances STAT3 signaling:  To test if BCL9 interacts with 
STAT3, whole cell extracts of DCIS.COM and SUM225 were co-immunoprecipitated with anti-
BCL9 antibody followed by Western blot with anti-STAT3 antibody. As shown in Figure 3.6, 
BCL9 and STAT3 interacted with each other in both cell lines. In addition, an inducible STAT3-
responsive firefly luciferase construct was utilized to measure STAT3 signaling activity in 293T 
cells that were non-transfected (control) or transiently transfected with: constitutively active 
STAT3 (CA-STAT3), pCDH-BCL9-overexpression vector (BCL9), or both (CA-
STAT3+BCL9). As seen in Figure 3.7, BCL9 overexpression significantly enhanced STAT3 
signaling compared to control (4.54 ± 0.22 fold vs. 1.0 ± 0.07 fold; P<0.05), and BCL9+CA-
STAT3 significantly increased STAT3 activity compared to CA-STAT3 alone (P<0.01). These 
findings support that BCL9 regulates STAT3 signaling. Furthermore, Western blot analysis of 
BCL9-KD and control DCIS.COM and SUM225 cells with phosphor(Ser727)STAT3 showed 
reduced phosphorylated STAT3 levels with BCL9 KD, suggesting that BCL9 does not only bind 
STAT3 but also mediates STAT3 activation (Figure 3.8).  
 
3.4. Discussion 
In chapter two, it was demonstrated that BCL9 is upregulated in both DCIS models, and that 
BCL9 knockdown inhibited proliferation, migration and invasion in both cell lines in vitro and in 
vivo. It was also shown that these effects were mediated through the WNT signaling pathway in 
case of the basal cell line (DCIS.COM), while the HER2 overexpressing cell line (SUM225) 
lacked WNT signaling. In this chapter, RPPA, and TCGA data analysis provide evidence that 
BCL9 levels correlate with phosphor(Tyr705)STAT3 and phosphor-EGFR protein levels . These 





Figure 3.6. BCL9 IP followed by Western blotting demonstrated binding of BCL9 to β-







Figure 3.7. BCL9 overexpression enhances STAT3 signaling activity in 293T cells. Bar 
graph represent STAT3 reporter activity in 293T cells non-transfected (control) or transiently 
transfected with: constitutively active STAT3 (CA-STAT3), pCDH-BCL9-overexpression 
vector (BCL9), or both (CA-STAT3+BCL9). The reporter is a mixture of inducible STAT3-
responsive firefly luciferase construct and constitutively expressing Renilla luciferase 







Figure 3.8. BCL9 KD cells showed reduced STAT3 activation. Representative Western 
blot analysis of cell lysates from control and BCL9-KD cells blotted with anti-BCL9, anti-






The mechanism for BCL9 mediated activation of STAT3 signaling maybe by enhancement in 
the transcription of tyrosine/serine kinases. STAT3 tyrosine phosphorylation occurs by receptor 
associated JAK kinases, and Src-family members, and is associated with STAT3 activation. 
Previous studies showed that inhibition of Src and JAKs decreased STAT3 activity and thus 
growth and survival of human breast cancer cells [121]. STAT3 serine phosphorylation is 
mediated by MAPK, p53, and JNK [122]. Further studies will need to assess levels of these 
kinases in BCL9 knockdown DCIS cells. Table 3.1, already showed downregulation of Src in 
BCL9-KD DCIS.COM and SUM225 cells, which supports that BCL9 may modulate this kinase. 
However, results need confirmation by Western blot analysis for phospho-proteins.  
Another mechanism by which BCL9 might be regulating STAT3 is through secreted 
cytokines and growth factors, growth factor receptors. Interestingly, Zhu, et al. 2015 showed that 
BCL9 mediated the expression and secretion of Cyclophillin-A from bone marrow endothelial 
cells. Cyclophillin-A binds CD147 on multiple myeloma cells thereby increasing STAT3 
expression and tumor colonization and growth [123]. EGFR is an activator of STAT3 signaling, 
and it serves as transcriptional coactivator that binds STAT3 in the nucleus [124]. Studies also 
showed EGFR to be a direct target of WNT/β-catenin signaling pathway [125]. EGFR was down 
regulated in the RPPA analysis, which might be a direct result of inhibition of β-catenin/BCL9 
mediated transcriptional activity.  
Co-immunoprecipitation experiments and IF co-staining revealed a novel interaction between 
BCL9 and STAT3. As described in the introduction, BCL9 possesses a potent transactivation 
domain in the HD4-HD5 region that enables it to activate transcription independent of Pygo [72]. 
This observation suggests that STAT3 may also serve as a binding partner for BCL9 either 
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directly or as part of a complex. Further studies will be necessary to evaluate BCL9-STAT3 
interactions, these would include in vitro coupled transcription/translation reactions, and 
Chromatin Re-Immunoprecipitation (Re-ChIP) assays. 
3.5. Conclusion 
The working model derived from these results is illustrated in Figure 3.9. When BCL9 is 
altered in a subset of DCIS lesions, the concept is that it will either bind β-catenin or STAT3 to 
activate transcription of an upstream STAT3 signaling activator that will in turn cause further 
STAT3 activation. Activation of STAT3 signaling will induce transcription of protumorigenic 
genes. Future studies will identify these secreted factors/kinases. Disrupting this positive 
feedback cycle by inhibiting BCL9 to STAT3 interaction could be a new powerful and effective 






Figure 3.9.  A model of BCL9 and STAT3 collaboration demonstrating how BCL9 and 


















4.1. Introduction  
Various risk stratification methods have been developed to identify DCIS patients at low, 
intermediate, and high risk of recurrence after breast conserving surgery, and who will benefit 
from radiotherapy after surgery. These methods are based on clinical, radiological, and 
pathological risk stratification systems, but none has shown value in predicting invasive 
recurrence. Molecular profiling is a new strategy to classify DCIS lesions into subgroups based 
on their risk of recurrence. There are several studies that involve gene expression profiling in 
DCIS to understand the molecular changes linked to development of invasion from DCIS [126]. 
However, few of these studies focus on the association between gene expression changes and 
risk of local recurrence. One retrospective study utilized DCIS lesions from 327 patients who 
had undergone surgery but not radiation; in this study, genomic profiling correlated with local 
recurrence rate, and yielded a DCIS recurrence score based on seven cancer genes and five 
reference genes [11]. Recent studies demonstrated some utility in using expression of a limited 
gene set for predicting DCIS recurrence; however, general use of this system is controversial 
[126]. Thus, finding biomarkers of DCIS high risk for recurrence is still a research priority in 
breast cancer. 
As shown in chapter two, total BCL9 expression in human breast cancer samples correlated 
with progression to invasion, and preliminary studies showed heterogeneous BCL9 expression 
patterns in pure DCIS. Thus, it has been hypothesized that BCL9 alone or as part of an 
expression signature can mark DCIS lesions that have higher risk of invasion. In this chapter, the 





4.2. Materials and Methods 
Patient samples for analysis of BCL9 as a potential biomarker of high risk: Tissue 
sections for BCL9 analysis were provided by Dr. Jeffrey Marks (Duke University) as a part of 
the NIH’s Early Detection Research Network (EDRN) GYN/Breast working group initiative to 
validate biomarkers that may predict a greater risk of invasive breast cancer or bad prognosis 
disease. These samples were identified, procured, and sectioned, stored, and maintained under a 
Duke approved protocol (eIRB Pro00027811, J. Marks, PI).  Two categories were defined: 
cases of DCIS that progressed to invasive cancer in the same breast between 1.8 and 17.6 years 
after initial diagnosis and controls of DCIS that did not progress (either recurrent DCIS or 
invasive cancer) over a minimum of 10 year follow-up. Controls were further selected based on 
size and nuclear grade to match or exceed case size. The Van Nuys index (Silverstein, Lancet 
1995) for controls had a higher median value than that of the cases (p=0.04).   
Statistical analysis: Data are presented as mean normalized expression ± s.e.m.  Unless 
otherwise noted, one-way analysis of variance (ANOVA) was used for statistical comparisons. A 
value of P≤0.05 was considered significant.  
Immunofluorescence staining (IF): IF was performed as previously described [33]. 
Antibodies are listed in Table 2.1. The acquisition software used was Pascal (Carl Zeiss 
MicroImaging, Inc). Fluorescence quantitation and analysis was done using MetaMorph® 








Enhanced BCL9 nuclear expression in DCIS with invasive component. To evaluate BCL9 
as a potential biomarker for DCIS with high risk of recurrence, the pattern of BCL9 expression 
was initially examined using a tissue microarray (TMA) composed of eight patient DCIS 
samples: 3 DCIS with IDC and 5 pure DCIS. Figure 4.1 illustrates the 3 patterns of staining 
observed: weak cytoplasmic staining (adjacent normal; Figure 4.1A, left panel); mixed nuclear 
and cytoplasmic (Figure 4.1A, middle panel and Figure 4.1B, lower panel); and enhanced 
nuclear expression (Figure 4.1A, right panel and Figure 4.1B, top panel). All adjacent normal 
breast epithelial cells expressed weak cytoplasmic BCL9 expression (similar to Figure 4.1A, left 
panel). Strikingly, all DCIS with IDC cases exhibited >90% enhanced nuclear expression 
(similar to Figure 4.1A right panel). Interestingly, enhanced BCL9 nuclear expression was 
associated with a loss of cytokeratin expression, which is indicative of EMT (as seen in Figure 
4.1A, right panel). Although increased expression of BCL9 was also observed in stromal 
macrophages (Figure 4.1A, right panel), the role of BCL9 in these cells is beyond the scope of 
this study. Among the pure DCIS cases, comedo or cribriform DCIS exhibited enhanced BCL9 
nuclear expression; papillary DCIS cases showed mixed nuclear and cytoplasmic BCL9 
expression (data not shown). 
To quantify BCL9 protein expression, IF staining with anti-BCL9, anti-K5/K19 and DAPI 
was performed on tissue microarrays from 30 pure DCIS and 62 DCIS with IDC patients. 
Nuclear and cytoplasmic median integrated density was quantified using Metamorph® 
Microscopy Automation and Image Analysis Software. As shown in Figure 4.2, pure DCIS 
lesions have a wider range of nuclear BCL9-median integrated density values, which reflects the 





Figure 4.1.  BCL9 may serve as a biomarker of high risk DCIS. (A) IF staining using anti-
BCL9 antibody (red), anti-K5/K19 (green), and counterstained with DAPI (blue) in patient 
DCIS samples with and without invasion, and in normal adjacent human breast epithelial 
cells. (B) Representative IF images for patient DCIS samples with the above antibodies, 







Figure 4.2.  BCL9 nuclear expression is higher in DCIS/IDC than in pure DCIS cases. 
Representative box plots of median nuclear BCL9 integrated density measured by Metamorph 
software in pure DCIS and DCIS/IDC cases. The groups represent measurements from 
adjacent normal tissue and DCIS in pure DCIS cases, and adjacent normal tissue, DCIS 
component and IDC component in DCIS/IDC cases. The box plots represent means and the 






integrated density values than pure DCIS (1,007,000 ± 58,940 compared to 519,531 ± 91,248; 
Mean ± s.e.m, P<0.0001). Furthermore, there was no significant difference between BCL9 
expression in the DCIS component and IDC component of DCIS with IDC cases. These data 
suggest that BCL9 pattern is more useful in sub-classifying pure DCIS lesions before they 
become invasive. 
Enhanced BCL9 nuclear expression in high risk DCIS.  Since high nuclear BCL9 
expression is present in DCIS with concurrent IDC, it may mean that this pattern predicts 
aggressive behavior; however, we do not know whether the pure DCIS cases will recur, nor do 
we know whether or not the lesions were completely excised, which could of course ensure a 
favorable outcome, even if the pure DCIS lesions with nuclear BCL9 were more aggressive. To 
begin to address this question the pattern of BCL9 expression, was examined in a patient set 
comprised of 28 pure DCIS samples with over 10 year followup (Figure 4.3). In this set, BCL9 
localization was compared with pathologic variables that correlated with aggressive behavior and 
high risk for recurrence: nuclear grade, hormone receptor status and human epidermal growth 
factor receptor 2 (HER2) expression [127]. This analysis showed that DCIS lesions expressing 
higher numbers of nuclear BCL9 positive cells were more likely to be ER negative (P=0.004; 
Wilcoxon rank-sum test), PR negative (P=0.003; Wilcoxon rank-sum test), high nuclear grade 
(Spearman correlation=0.49; P=0.008), and high HER2 expressing (Spearman correlation=0.56; 
P=0.002; Figure 4.3). Based on these data, BCL9 may serve as a biomarker if validated in a 






Figure 4.3.  Statistical analysis of tissue sections from 28 patients with pure DCIS 
analyzed by IF using anti-BCL9 antibody. This analysis showed that the percent of cells 
expressing nuclear BCL9 was significantly higher in DCIS that were ER negative (P=0.004; 
Wilcoxon rank-sum test), PR negative (P=0.003; Wilcoxon rank-sum test) (A), high HER2 
(Spearman correlation =0.56; P=0.002), and high nuclear grade (Spearman correlation=0.49; 
P=0.008) (B). Median percent of cells positive for nuclear BCL9 (IQR=interquartile range) 
for ER positive samples = 8% (1%, 40%); for PR positive = 8% (1%, 35%); ER negative = 






BCL9 gene is altered in breast cancers. Interestingly, analysis of TCGA data (provisional 
TCGA; 959 cases) (http://cancergenome.nih.gov/) showed that 26% of invasive breast cancers 
contain BCL9 gene alterations.  The majority of these alterations include amplification (13%) 
and mRNA upregulation (17%).  This is a significant level of gene alteration compared to ESR1 
(8%), ERBB2 (19%) and BCL9L (5%) (Figure 4.4). Furthermore, BCL9 amplification is 
observed in a significantly higher proportion of invasive basal breast cancer (BLBC) subtypes 
compared to other subtypes (Figure 4.5) [110, 113]. Moreover, there is a significant association 
between BCL9 gene amplification and mRNA upregulation (Figure 4.6). These data suggest that 
BCL9 may predispose to development of basal like invasive breast cancers. The TCGA data 
were also analyzed for the expression of differentially expressed genes in breast cancers that 
showed BCL9 mRNA upregulation.  BCL9 upregulation was defined as BCL9 expression levels 
above the range observed by normal samples. IPA analysis on the differentially expressed genes 
showed WNT/β-catenin pathway to be significantly upregulated in BCL9 high compared to 





Figure 4.4.  A significant proportion of breast cancers show BCL9 gene alteration. (A) 
TCGA Provisional data shows that 26% of invasive breast cancers (total of 959 cases) contain 
a genetic alteration in BCL9 gene; the majority of these consist of gene amplification and 
mRNA up-regulation. This is a significant level of genetic alteration when compared to 
ERBB2 (19%), ESR1 (8%) and BCL9L (5%). (B) BCL9 gene alterations across all cancers.  
BCL9 gene is altered in many cancers including breast, liver and bladder.  The arrow points to 







Figure 4.5. BCL9 genomic alteration is higher in basal breast cancers. TCGA data shows 
that a significantly higher proportion of basal breast cancers contain BCL9 genomic 








Figure 4.6. Correlation between BCL9 mRNA expression and BCL9 amplification.  The 
gene expression data was available as z-score.  Diploid classification was used to identify 
median gene expression value, and this value was used as the cut off for dichotomizing gene 
expression as low (<= median) or high (>median) for BCL9 expression.  Contingency tables 
were created for diploid vs amplified or gain vs amplified against low or high BCL9 
expression.  Chi-square analysis indicates significant association between BCL9 amplification 






In this chapter, evaluation of pure DCIS, and DCIS with IDC revealed different BCL9 
expression patterns within the same patient and between different DCIS cases. BCL9 staining 
was observed to be nuclear, or cytoplasmic or both.  This pattern is consistent with a study by 
Hyeon, et al. 2013 in hepatocellular carcinoma (HCC) patients [81], where BCL9 expression had 
cytoplasmic weak to moderate intensity in normal hepatocytes, while in HCC BCL9 was 
observed in nuclei with or without cytoplasmic expression [81]. Our hypothesis is that BCL9 
nuclear expression is associated with risk of invasion. By analysis of 28 DCIS patient samples, It 
has been demonstrated that DCIS lesions expressing higher nuclear BCL9 (% cells expressing 
nuclear BCL9) were more likely to be ER negative, PR negative, high nuclear grade, and high in 
HER2 expression. These characteristics are associated with higher recurrence rate in DCIS [127]. 
In chapter two, we described that BCL9 expression pattern was different from that of BCL9 
homolog-BCL9L during progression, which was predominantly cytoplasmic. This finding was 
different from what other studies described. Toya et al. 2007 demonstrated that BCL9L 
expression was nuclear in invasive lesions and was associated with high nuclear grade and HER2 
positivity [106]. Another study showed overexpression of BCL9L in ER positive tumors and that 
tamoxifen treated patients had better survival rates [107].  However, no studies had evaluated 
BCL9 staining in DCIS patients.  
Interestingly, TCGA data analysis revealed that BCL9 gene alterations were found in 26% of 
all breast cancers, the majority of which were gene amplifications (13%) or overexpression 
(17%). For future studies, Fluorescence in situ hybridization (FISH) will be performed on DCIS 
tissue microarrays to evaluate the association between BCL9 copy numbers in DCIS lesions and 




Here, the prognostic significance of BCL9 was evaluated in primary DCIS cases. Analysis of 
30 pure DCIS and 62 DCIS with IDC patient samples revealed that BCL9 expression is 
significantly higher in DCIS/IDC than in pure DCIS cases. It was shown that nuclear BCL9 was 
associated with low ER, PR, and high HER2. Therefore, BCL9 may serve as a potential future 
biomarker of high risk DCIS if validated in a large dataset of DCIS patients with known 
outcome. Furthermore, evaluation of the adjacent normal mammary tissue for BCL9 protein 















DCIS is the most common premalignant lesion of the breast. With the development of 
advanced breast cancer screening methods, diagnosis of DCIS cases is increasing. DCIS patients 
are treated with lumpectomy alone or lumpectomy with radiotherapy. Hormonal therapy is also 
added to the treatment regimen depending on the ER status of the DCIS lesions. The major 
problem in DCIS management is lack of risk stratification methods to separate patients who 
benefit from lumpectomy alone from other patients who require radiotherapy and surgery. As a 
result, many DCIS patients are potentially over-treated. The aims of our studies was to identify 
new and more effectivetherapeutic strategies to prevent recurrence, and to identify biomarkers 
for DCIS patients who have potential risk of invasive progression.  
Toward these aims, we utilized two in vivo models to perform gene expression profiling 
and to screen for molecular changes during progression from DCIS to IDC. This led to discovery 
of a novel role of BCL9 in breast cancer tumorigenesis.  
In chapter two, we showed that BCL9 knockdown inhibited proliferation, migration and 
invasion, and regulated EMT biomarkers in our DCIS cell lines. We confirmed that BCL9 exerts 
its pro-tumorigenic effects through activating β-catenin mediated WNT signaling. Future studies 
will focus on identifying small molecule or peptide inhibitors that target BCL9 by disrupting its 
binding with β-catenin and other binding partners such as PYGO. Takada et al. developed a 
stabilized α helix of BCL9 (SAH-BCL9). SAH-BCL9 disrupts β-catenin/BCL9 binding, and 
selectively suppresses WNT transcription, and thus exhibits mechanism-based antitumor effects 
[86]. Similarly, a recent study by de la Roche and colleagues screened for small molecular 
inhibitors of β-catenin binding to BCL9 [88]. Their screen identified that carnosic acid (CA), a 
natural compound found in rosemary, inhibited BCL9/β-catenin binding and attenuated β-catenin 
dependent transcription [88]. CA inhibited the growth of MCF7 human breast cancer cells [129]. 
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CA is orally bioavailable and may be administered by oral gavage and or by administration of a 
compounded flavored tablet to mice. If our studies demonstrate efficacy for prevention of DCIS-
IDC transition, CA may serve as a future therapy to prevent IDC recurrence following DCIS 
treatment.  
In chapter three, we shed light on a new mechanism by which BCL9 might promote 
DCIS invasion through STAT3 signaling. BCL9 showed an interaction with STAT3 and 
increased STAT3 signaling activity. Interestingly, BCL9 protein levels correlated with 
phosphorylated STAT3 protein levels in TCGA analysis of 959 breast cancers. This finding 
suggests that BCL9 indirectly activates and phosphorylates STAT3 either at the receptor level or 
by modulating kinase activity. However, the mechanism by which BCL9 contributes to STAT3 
signaling requires further investigation. Future studies will identify BCL9-mediated secreted 
factors that stimulate STAT3 signaling, and screen for kinases that are regulated by BCL9. In 
addition, future experiments will evaluate the transcriptional activity of the STAT3/BCL9 
complex. 
In chapter four, we evaluated BCL9 as a biomarker for high risk DCIS. BCL9 nuclear 
expression was higher in DCIS cases that were associated with IDC when compared with pure 
DCIS. Nuclear BCL9 levels were higher in DCIS lesions that exhibited characteristics of high-
risk DCIS, such as ER-negative, PR-negative, HER2-positive, and high nuclear grade. For the 
future, these studies will be validated in a larger group of patients with appropriately matched 
cases and controls based on age at DCIS diagnosis (+/- 5 years), year of DCIS diagnosis (+/- 2.5 
years), surgical treatment (in the following categories: biopsy only, lumpectomy without or 
without nodal dissection, and mastectomy), and radiation (yes vs. no). Associations between 
nuclear BCL9 in the DCIS lesion and invasive outcome will be analyzed. 
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In addition, we observed BCL9-expressing macrophages recruited to DCIS lesions in our 
DCIS cell line MIND xenografts and in primary patient DCIS. There is growing evidence that 
macrophages promote tumor initiation and progression. Macrophages are recruited to the sites of 
invasion by a number of chemokines and growth factors secreted by tumor epithelial cells such 
as colony stimulating factor-1 and CCL2. Macrophages in turn produce growth factors, EGF, 
VEGF, and MMP7/9 that promote tumor cell growth and invasion [130]. Furthermore, Oguma et 
al. have demonstrated that the release of TNF-α by macrophages enhanced canonical WNT 
signaling in gastric cancer epithelial cells [131]. These studies [132] suggested that interactions 
of BCL9-expressing macrophages with DCIS epithelia promote cancer progression. Although 
studying the role of BCL9 in recruiting macrophages is outside the scope of this dissertation, it 
would be interesting to evaluate BCL9-mediated macrophage-DCIS interactions. 
By studying BCL9 in DCIS we hope to identify new therapeutic opportunities to prevent 
DCIS progression and recurrence. Finding biomarkers such as BCL9 that alone or in 
combination with other existing biomarkers can predict future risk of DCIS/IDC development 
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